EU Clinical Trials Register

Clinical trial results:

A Phase 2b, Randomized, Double-Blind, Placebo Controlled Study of PF-06700841 to Evaluate the Efficacy at 16 Weeks and to Evaluate the Safety and Efficacy up to 1 Year in Subjects with Active Psoriatic Arthritis

Summary

EudraCT number	2018-004241-16
Trial protocol	SK HU CZ BG LT EE ES
Global end of trial date	15 January 2021

Results information

Result version number	v1 (current)
This version publication date	09 July 2021
First version publication date	09 July 2021

Trial information

Trial identification

Sponsor protocol code	B7931030

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03963401
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer, Inc
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc, +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc, +1 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 March 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	15 January 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to evaluate at Week 16 the efficacy of PF-06700841 in subjects with active Psoriatic Arthritis (PsA). The 36 weeks (Week 17 - Week 52) built in extension period was to provide an opportunity for all subjects to receive additional active study treatment up to 1 year.

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial subjects.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 June 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 7
Country: Number of subjects enrolled	Bulgaria: 27
Country: Number of subjects enrolled	Czechia: 37
Country: Number of subjects enrolled	Estonia: 6
Country: Number of subjects enrolled	Hungary: 3
Country: Number of subjects enrolled	Lithuania: 7
Country: Number of subjects enrolled	Poland: 80
Country: Number of subjects enrolled	Russian Federation: 37
Country: Number of subjects enrolled	Serbia: 4
Country: Number of subjects enrolled	Slovakia: 5
Country: Number of subjects enrolled	Spain: 5
Worldwide total number of subjects	218
EEA total number of subjects	170

Notes:

Subjects enrolled per age group

In utero	0

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	202
From 65 to 84 years	16
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study consisted of a screening period of up to 5 weeks, a double blind treatment period of 52 weeks, including a placebo controlled phase from Day 1 to Week 16 visits and an extended active treatment phase from Week 17 through Week 52.

Pre-assignment

Screening details:

A total of 219 subjects were enrolled in this study and 1 of them didn't receive any study treatment.

Period 1

Period 1 title	Initial Period (Day1-Week 16)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind[1]
Roles blinded	Subject, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	PF-06700841 60 mg QD -> PF-06700841 60 mg QD

Arm description:

PF-06700841 tablet was administered orally at 60 milligram (mg) once daily (QD) from Day 1 to Week 52.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 60 mg QD from Day 1 to Week 16.

Arm title	PF-06700841 30 mg QD -> PF-06700841 30 mg QD

Arm description:

PF-06700841 tablet was administered orally at 30 mg QD from Day 1 to Week 52.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 30 mg QD from Day 1 to Week 16.

Arm title	PF-06700841 10 mg QD -> PF-06700841 60 mg QD

Arm description:

PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.

Arm type	Experimental

Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 10 mg QD from Day 1 to Week 16.

Arm title	PF-06700841 10 mg QD -> PF-06700841 30 mg QD

Arm description:

PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 10 mg QD from Day 1 to Week 16.

Arm title	Placebo -> PF-06700841 60 mg QD

Arm description:

Placebo matched to PF-06700841 was administered
orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.

Arm type	Placebo
Investigational medicinal product name	Placebo matching PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received Placebo QD from Day 1 to Week 16.

Arm title	Placebo -> PF-06700841 30 mg QD

Arm description:

Placebo matched to PF-06700841 was administered
orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.

Arm type	Placebo
Investigational medicinal product name	Placebo matching PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received Placebo QD from Day 1 to Week 16.

Notes:

[1] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: This is a double-blind study where neither the subjects nor the experimenters know the particular treatment. Subjects, Care Provider, Outcome Assessor, where Carer and Assessor belongs to experimenters in above double blind criteria.

Number of subjects in period 1	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Started	60	60	16
Completed	57	57	14
Not completed	3	3	2
Consent withdrawn by subject	2	1	1
Adverse event, non-fatal	1	2	-
Lack of efficacy	-	-	1

Number of subjects in period 1	PF-06700841 10 mg QD -> PF-06700841 30 mg QD	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD
Started	15	34	33
Completed	13	31	31
Not completed	2	3	2
Consent withdrawn by subject	1	2	-
Adverse event, non-fatal	-	1	2
Lack of efficacy	1	-	-

Period 2

Period 2 title	Extension Period (Week 17- Week 52)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind[2]
Roles blinded	Subject, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	PF-06700841 60 mg QD -> PF-06700841 60 mg QD

Arm description:

PF-06700841 tablet was administered orally at 60 mg QD from Day 1 to Week 52.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 60 mg QD from Week 17 to Week 52.

Arm title	PF-06700841 30 mg QD -> PF-06700841 30 mg QD

Arm description:

PF-06700841 tablet was administered orally at 30 mg QD from Day 1 to Week 52.

Arm type	Experimental

Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 30 mg QD from Week 17 to Week 52.

Arm title	PF-06700841 10 mg QD -> PF-06700841 60 mg QD

Arm description:

PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 60 mg QD from Week 17 to Week 52.

Arm title	PF-06700841 10 mg QD -> PF-06700841 30 mg QD

Arm description:

PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 30 mg QD from Week 17 to Week 52.

Arm title	Placebo -> PF-06700841 60 mg QD

Arm description:

Placebo matched to PF-06700841 was administered
orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered
orally at 60 mg QD.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 60 mg QD from Week 17 to Week 52.

Arm title	Placebo -> PF-06700841 30 mg QD

Arm description:

Placebo matched to PF-06700841 was administered
orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered
orally at 30 mg QD.

Arm type	Experimental

Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	Brepocitinib
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received PF-06700841 30 mg QD from Week 17 to Week 52.

Notes:

[2] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: This is a double-blind study where neither the subjects nor the experimenters know the particular treatment. Subjects, Care Provider, Outcome Assessor, where Carer and Assessor belongs to experimenters in above double blind criteria.

Number of subjects in period 2	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Started	57	57	14
Completed	43	52	10
Not completed	14	5	4
Consent withdrawn by subject	4	1	-
Adverse event, non-fatal	6	3	2
Non-Compliance With Study Drug	1	-	-
Unspecified	1	1	-
No Longer Meets Eligibility Criteria	1	-	-
Lost to follow-up	-	-	1
Lack of efficacy	1	-	1

Number of subjects in period 2	PF-06700841 10 mg QD -> PF-06700841 30 mg QD	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD
Started	13	31	31
Completed	12	25	26
Not completed	1	6	5
Consent withdrawn by subject	-	1	1
Adverse event, non-fatal	-	4	3
Non-Compliance With Study Drug	-	-	-
Unspecified	1	1	1
No Longer Meets Eligibility Criteria	-	-	-
Lost to follow-up	-	-	-
Lack of efficacy	-	-	-

Baseline characteristics

Reporting groups

Reporting group title	PF-06700841 60 mg QD -> PF-06700841 60 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 60 milligram (mg) once daily (QD) from Day 1 to Week 52.	
Reporting group title	PF-06700841 30 mg QD -> PF-06700841 30 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 30 mg QD from Day 1 to Week 52.	
Reporting group title	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.	
Reporting group title	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.	
Reporting group title	Placebo -> PF-06700841 60 mg QD
Reporting group description:	
Placebo matched to PF-06700841 was administered orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.	
Reporting group title	Placebo -> PF-06700841 30 mg QD
Reporting group description:	
Placebo matched to PF-06700841 was administered orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.	

Reporting group values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Number of subjects	60	60	16
Age Categorical			
Units: Subjects			
18-44 Years	22	26	9
45-64 Years	35	31	5
>=65 Years	3	3	2
Age Continuous			
Units: Years			
arithmetic mean	48.68	45.85	47.81
standard deviation	± 11.47	± 10.23	± 14.16
Sex: Female, Male			
Units: Subjects			
Female	34	32	7
Male	26	28	9
Race/Ethnicity, Customized			
Units: Subjects			
White	59	60	16
Black or African American	0	0	0
Asian	1	0	0
Other	0	0	0

Ethnicity (NIH/OMB) Units: Subjects			
Not Hispanic or Latino	60	59	16
Not reported	0	1	0

Reporting group values	PF-06700841 10 mg QD -> PF-06700841 30 mg QD	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD
Number of subjects	15	34	33
Age Categorical Units: Subjects			
18-44 Years	6	13	14
45-64 Years	8	17	16
>=65 Years	1	4	3
Age Continuous Units: Years			
arithmetic mean	47.73	47.94	48.48
standard deviation	± 12.95	± 12.58	± 11.84
Sex: Female, Male Units: Subjects			
Female	7	20	16
Male	8	14	17
Race/Ethnicity, Customized Units: Subjects			
White	15	34	33
Black or African American	0	0	0
Asian	0	0	0
Other	0	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Not Hispanic or Latino	15	33	32
Not reported	0	1	1

Reporting group values	Total		
Number of subjects	218		
Age Categorical Units: Subjects			
18-44 Years	90		
45-64 Years	112		
>=65 Years	16		
Age Continuous Units: Years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male Units: Subjects			
Female	116		
Male	102		
Race/Ethnicity, Customized Units: Subjects			
White	217		
Black or African American	0		

Asian	1		
Other	0		
Ethnicity (NIH/OMB)			
Units: Subjects			
Not Hispanic or Latino	215		
Not reported	3		

Subject analysis sets

Subject analysis set title	Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Subjects who received Placebo matched to PF-06700841 through the initial 16-week treatment period.

Subject analysis set title	PF 06700841 10 mg QD
Subject analysis set type	Safety analysis

Subject analysis set description:

Subjects who received PF-06700841 tablet orally at 10 mg QD through the initial 16-week treatment period.

Subject analysis set title	PF 06700841 30 mg QD
Subject analysis set type	Safety analysis

Subject analysis set description:

Subjects who received PF-06700841 tablet orally at 30 mg QD through the initial 16-week treatment period.

Subject analysis set title	PF 06700841 60 mg QD
Subject analysis set type	Safety analysis

Subject analysis set description:

Subjects who received PF-06700841 tablet orally at 60 mg QD through the initial 16-week treatment period.

Reporting group values	Placebo	PF 06700841 10 mg QD	PF 06700841 30 mg QD
Number of subjects	67	31	60
Age Categorical			
Units: Subjects			
18-44 Years	27	15	26
45-64 Years	33	13	31
>=65 Years	7	3	3
Age Continuous			
Units: Years			
arithmetic mean			
standard deviation	±	±	±
Sex: Female, Male			
Units: Subjects			
Female	36	14	32
Male	31	17	28
Race/Ethnicity, Customized			
Units: Subjects			
White	67	31	60
Black or African American	0	0	0
Asian	0	0	0
Other	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			

Not Hispanic or Latino	65	31	59
Not reported	2	0	1

Reporting group values	PF 06700841 60 mg QD		
Number of subjects	60		
Age Categorical Units: Subjects			
18-44 Years	22		
45-64 Years	35		
>=65 Years	3		
Age Continuous Units: Years arithmetic mean standard deviation	±		
Sex: Female, Male Units: Subjects			
Female	34		
Male	26		
Race/Ethnicity, Customized Units: Subjects			
White	59		
Black or African American	0		
Asian	1		
Other	0		
Ethnicity (NIH/OMB) Units: Subjects			
Not Hispanic or Latino	60		
Not reported	0		

End points

End points reporting groups

Reporting group title	PF-06700841 60 mg QD -> PF-06700841 60 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 60 milligram (mg) once daily (QD) from Day 1 to Week 52.	
Reporting group title	PF-06700841 30 mg QD -> PF-06700841 30 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 30 mg QD from Day 1 to Week 52.	
Reporting group title	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.	
Reporting group title	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.	
Reporting group title	Placebo -> PF-06700841 60 mg QD
Reporting group description:	
Placebo matched to PF-06700841 was administered orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.	
Reporting group title	Placebo -> PF-06700841 30 mg QD
Reporting group description:	
Placebo matched to PF-06700841 was administered orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.	
Reporting group title	PF-06700841 60 mg QD -> PF-06700841 60 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 60 mg QD from Day 1 to Week 52.	
Reporting group title	PF-06700841 30 mg QD -> PF-06700841 30 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 30 mg QD from Day 1 to Week 52.	
Reporting group title	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.	
Reporting group title	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Reporting group description:	
PF-06700841 tablet was administered orally at 10 mg QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.	
Reporting group title	Placebo -> PF-06700841 60 mg QD
Reporting group description:	
Placebo matched to PF-06700841 was administered orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 60 mg QD.	
Reporting group title	Placebo -> PF-06700841 30 mg QD
Reporting group description:	
Placebo matched to PF-06700841 was administered orally QD from Day 1 to Week 16. From Week 17 to Week 52, PF-06700841 tablet was administered orally at 30 mg QD.	
Subject analysis set title	Placebo
Subject analysis set type	Safety analysis

Subject analysis set description:

Subjects who received Placebo matched to PF-06700841 through the initial 16-week treatment period.

Subject analysis set title	PF 06700841 10 mg QD
Subject analysis set type	Safety analysis

Subject analysis set description:

Subjects who received PF-06700841 tablet orally at 10 mg QD through the initial 16-week treatment period.

Subject analysis set title	PF 06700841 30 mg QD
Subject analysis set type	Safety analysis

Subject analysis set description:

Subjects who received PF-06700841 tablet orally at 30 mg QD through the initial 16-week treatment period.

Subject analysis set title	PF 06700841 60 mg QD
Subject analysis set type	Safety analysis

Subject analysis set description:

Subjects who received PF-06700841 tablet orally at 60 mg QD through the initial 16-week treatment period.

Primary: Percentage of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16

End point title	Percentage of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response at Week 16

End point description:

The ACR (American College of Rheumatology) Criteria is a standard criteria to measure the effectiveness of various arthritis medications or treatments in clinical trials for Rheumatoid Arthritis. The ACR's definition for calculating improvement in rheumatoid arthritis (ACR20) is calculated as a >=20% improvement in tender and swollen joint counts and >=20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute phase reactant. Number of subjects analyzed: All subjects who received at least 1 dose of the randomized study treatment and had ACR response.

End point type	Primary

End point timeframe:

Week 16

End point values	Placebo	PF 06700841 10 mg QD	PF 06700841 30 mg QD	PF 06700841 60 mg QD
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	67	31	60	59
Units: Percentage of subjects				
number (confidence interval 95%)	43.28 (31.42 to 55.15)	64.52 (47.67 to 81.36)	66.67 (54.74 to 78.59)	74.58 (63.47 to 85.69)

Statistical analyses

Statistical analysis title	Placebo, PF-06700841 10 mg QD
Comparison groups	PF 06700841 10 mg QD v Placebo

Number of subjects included in analysis	98
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1172
Method	Normal Approximation,Dunnett's Method
Parameter estimate	Percentage difference
Point estimate	21.23
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.94
upper limit	38.52
Variability estimate	Standard error of the mean
Dispersion value	10.51

Statistical analysis title	Placebo, PF-06700841 30 mg QD
Comparison groups	Placebo v PF 06700841 30 mg QD
Number of subjects included in analysis	127
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0197
Method	Normal Approximation,Dunnett's Method
Parameter estimate	Percentage difference
Point estimate	23.38
Confidence interval	
level	90 %
sides	2-sided
lower limit	9.26
upper limit	37.5
Variability estimate	Standard error of the mean
Dispersion value	8.58

Statistical analysis title	Placebo, PF-06700841 60 mg QD
Comparison groups	Placebo v PF 06700841 60 mg QD
Number of subjects included in analysis	126
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0006
Method	Normal Approximation,Dunnett's Method
Parameter estimate	Percentage difference
Point estimate	31.29
Confidence interval	
level	90 %
sides	2-sided
lower limit	17.65
upper limit	44.93

Variability estimate	Standard error of the mean
Dispersion value	8.29

Secondary: Percentage of Tumor Necrosis Factor (TNF) Inhibitor-Naïve Subjects Achieving an ACR20 response at Week 16

End point title	Percentage of Tumor Necrosis Factor (TNF) Inhibitor-Naïve Subjects Achieving an ACR20 response at Week 16

End point description:

The ACR (American College of Rheumatology) Criteria is a standard criteria to measure the effectiveness of various arthritis medications or treatments in clinical trials for Rheumatoid Arthritis. The ACR's definition for calculating improvement in rheumatoid arthritis (ACR20) is calculated as a >=20% improvement in tender and swollen joint counts and >=20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute phase reactant. Number of Subjects analyzed: All subjects who received at least 1 dose of the randomized study treatment with prior TNFi naive and had ACR response.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo	PF 06700841 10 mg QD	PF 06700841 30 mg QD	PF 06700841 60 mg QD
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	60	28	56	55
Units: Percentage of subjects				
number (confidence interval 95%)	43.33 (30.79 to 55.87)	64.29 (46.54 to 82.03)	69.64 (57.60 to 81.69)	74.55 (63.03 to 86.06)

Statistical analyses

Statistical analysis title	Placebo, PF-06700841 10 mg QD
Comparison groups	Placebo v PF 06700841 10 mg QD
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0588
Method	normal approximation
Parameter estimate	Percentage difference
Point estimate	20.95
Confidence interval	
level	90 %
sides	2-sided
lower limit	2.72
upper limit	39.19
Variability estimate	Standard error of the mean
Dispersion value	11.09

Statistical analysis title	Placebo, PF-06700841 30 mg QD
Comparison groups	Placebo v PF 06700841 30 mg QD
Number of subjects included in analysis	116
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	normal approximation
Parameter estimate	Percentage difference
Point estimate	26.31
Confidence interval	
level	90 %
sides	2-sided
lower limit	11.72
upper limit	40.9
Variability estimate	Standard error of the mean
Dispersion value	8.87

Statistical analysis title	Placebo, PF 06700841 60 mg QD
Comparison groups	Placebo v PF 06700841 60 mg QD
Number of subjects included in analysis	115
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	normal approximation
Parameter estimate	Percentage difference
Point estimate	31.21
Confidence interval	
level	90 %
sides	2-sided
lower limit	16.93
upper limit	45.5
Variability estimate	Standard error of the mean
Dispersion value	8.68

Secondary: Percentage of Subjects Achieving an ACR20 Response at All Treatment Timepoints (except Week 16): Week 2, 4, 8, 12, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving an ACR20 Response at All Treatment Timepoints (except Week 16): Week 2, 4, 8, 12, 20, 28, 36, 44, and 52

End point description:

The ACR (American College of Rheumatology) Criteria is a standard criteria to measure the effectiveness of various arthritis medications or treatments in clinical trials for Rheumatoid Arthritis. The ACR's definition for calculating improvement in rheumatoid arthritis (ACR20) is calculated as a >=20% improvement in tender and swollen joint counts and >=20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute phase

reactant. Number of subjects analyzed: All subjects who received at least 1 dose of the randomized study treatment and had ACR response.

End point type	Secondary
End point timeframe: Week 2, 4, 8, 12, 20, 28, 36, 44, and 52	

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	21.67 (11.24 to 32.09)	18.33 (8.54 to 28.12)	18.75 (0.00 to 37.87)	3.13 (0.00 to 11.65)
Week 4	45.00 (32.41 to 57.59)	51.67 (39.02 to 64.31)	31.25 (8.54 to 53.96)	20.00 (0.00 to 40.24)
Week 8	66.67 (54.74 to 78.59)	55.00 (42.41 to 67.59)	50.00 (25.50 to 74.50)	40.00 (15.21 to 64.79)
Week 12	70.00 (58.40 to 81.60)	63.33 (51.14 to 75.53)	56.25 (31.94 to 80.56)	60.00 (35.21 to 84.79)
Week 20	81.67 (71.88 to 91.46)	80.00 (69.88 to 90.12)	68.75 (46.04 to 91.46)	60.00 (35.21 to 84.79)
Week 28	73.33 (62.14 to 84.52)	78.33 (67.91 to 88.76)	68.75 (46.04 to 91.46)	73.33 (50.95 to 95.71)
Week 36	66.67 (54.74 to 78.59)	78.33 (67.91 to 88.76)	68.75 (46.04 to 91.46)	80.00 (59.76 to 100.00)
Week 44	68.33 (56.56 to 80.10)	73.33 (62.14 to 84.52)	62.50 (38.78 to 86.22)	73.33 (50.95 to 95.71)
Week 52	61.67 (49.36 to 73.97)	70.00 (58.40 to 81.60)	56.25 (31.94 to 80.56)	60.00 (35.21 to 84.79)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	5.88 (0.00 to 13.79)	18.18 (5.02 to 31.34)		
Week 4	14.71 (2.80 to 26.61)	24.24 (9.62 to 38.86)		
Week 8	35.29 (19.23 to 51.36)	42.42 (25.56 to 59.29)		
Week 12	44.12 (27.43 to 60.81)	39.39 (22.72 to 56.07)		
Week 20	73.53 (58.70 to 88.36)	75.76 (61.14 to 90.38)		
Week 28	64.71 (48.64 to 80.77)	81.82 (68.66 to 94.98)		

Week 36	64.71 (48.64 to 80.77)	81.82 (68.66 to 94.98)		
Week 44	67.65 (51.92 to 83.37)	75.76 (61.14 to 90.38)		
Week 52	61.76 (45.43 to 78.10)	66.67 (50.58 to 82.75)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving an ACR50 Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving an ACR50 Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The ACR (American College of Rheumatology) Criteria is a standard criteria to measure the effectiveness of various arthritis medications or treatments in clinical trials for Rheumatoid Arthritis. The ACR's definition for calculating improvement in rheumatoid arthritis (ACR50) is calculated as a >=50% improvement in tender and swollen joint counts and >=50% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute phase reactant. Number of subjects analyzed: All subjects who received at least 1 dose of the randomized study treatment and had ACR response.

End point type	Secondary

End point timeframe:

Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	6.67 (0.35 to 12.98)	1.67 (0.00 to 4.91)	2.94 (0.00 to 10.97)	3.13 (0.00 to 11.65)
Week 4	13.33 (4.73 to 21.93)	16.67 (7.24 to 26.10)	2.94 (0.00 to 10.97)	6.67 (0.00 to 19.29)
Week 8	31.67 (19.90 to 43.44)	25.00 (14.04 to 35.96)	18.75 (0.00 to 37.87)	13.33 (0.00 to 30.54)
Week 12	43.33 (30.79 to 55.87)	31.67 (19.90 to 43.44)	31.25 (8.54 to 53.96)	20.00 (0.00 to 40.24)
Week 16	44.07 (31.40 to 56.74)	48.33 (35.69 to 60.98)	31.25 (8.54 to 53.96)	33.33 (9.48 to 57.19)
Week 20	61.67 (49.36 to 73.97)	53.33 (40.71 to 65.96)	37.50 (13.78 to 61.22)	40.00 (15.21 to 64.79)
Week 28	56.67 (44.13 to 69.21)	51.67 (39.02 to 64.31)	43.75 (19.44 to 68.06)	53.33 (28.09 to 78.58)
Week 36	53.33 (40.71 to 65.96)	56.67 (44.13 to 69.21)	50.00 (25.50 to 74.50)	66.67 (42.81 to 90.52)
Week 44	56.67 (44.13 to 69.21)	55.00 (42.41 to 67.59)	43.75 (19.44 to 68.06)	60.00 (35.21 to 84.79)

Week 52	46.67 (34.04 to 59.29)	58.33 (45.86 to 70.81)	43.75 (19.44 to 68.06)	46.67 (21.42 to 71.91)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	1.43 (0.00 to 5.36)	1.47 (0.00 to 5.52)		
Week 4	2.94 (0.00 to 8.62)	6.06 (0.00 to 14.20)		
Week 8	11.76 (0.93 to 22.59)	15.15 (2.92 to 27.38)		
Week 12	23.53 (9.27 to 37.79)	12.12 (0.99 to 23.26)		
Week 16	14.71 (2.80 to 26.61)	6.06 (0.00 to 14.20)		
Week 20	44.12 (27.43 to 60.81)	45.45 (28.47 to 62.44)		
Week 28	41.18 (24.63 to 57.72)	66.67 (50.58 to 82.75)		
Week 36	50.00 (33.19 to 66.81)	57.58 (40.71 to 74.44)		
Week 44	58.82 (42.28 to 75.37)	63.64 (47.22 to 80.05)		
Week 52	41.18 (24.63 to 57.72)	51.52 (34.46 to 68.57)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving an ACR70 Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving an ACR70 Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The ACR (American College of Rheumatology) Criteria is a standard criteria to measure the effectiveness of various arthritis medications or treatments in clinical trials for Rheumatoid Arthritis. The ACR's definition for calculating improvement in rheumatoid arthritis (ACR70) is calculated as a >=70% improvement in tender and swollen joint counts and >=70% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute phase reactant. Number of subjects analyzed: All subjects who received at least 1 dose of the randomized study treatment and had ACR response.

End point type	Secondary

End point timeframe:

Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	3.33 (0.00 to 7.88)	1.67 (0.00 to 4.91)	2.94 (0.00 to 10.97)	3.13 (0.00 to 11.65)
Week 4	5.00 (0.00 to 10.51)	5.00 (0.00 to 10.51)	2.94 (0.00 to 10.97)	3.13 (0.00 to 11.65)
Week 8	11.67 (3.54 to 19.79)	11.67 (3.54 to 19.79)	6.25 (0.00 to 18.11)	3.13 (0.00 to 11.65)
Week 12	21.67 (11.24 to 32.09)	18.33 (8.54 to 28.12)	6.25 (0.00 to 18.11)	6.67 (0.00 to 19.29)
Week 16	23.73 (12.87 to 34.58)	26.67 (15.48 to 37.86)	6.25 (0.00 to 18.11)	13.33 (0.00 to 30.54)
Week 20	35.00 (22.93 to 47.07)	30.00 (18.40 to 41.60)	12.50 (0.00 to 28.70)	20.00 (0.00 to 40.24)
Week 28	36.67 (24.47 to 48.86)	38.33 (26.03 to 50.64)	18.75 (0.00 to 37.87)	26.67 (4.29 to 49.05)
Week 36	40.00 (27.60 to 52.40)	35.00 (22.93 to 47.07)	37.50 (13.78 to 61.22)	26.67 (4.29 to 49.05)
Week 44	46.67 (34.04 to 59.29)	45.00 (32.41 to 57.59)	37.50 (13.78 to 61.22)	40.00 (15.21 to 64.79)
Week 52	38.33 (26.03 to 50.64)	45.00 (32.41 to 57.59)	31.25 (8.54 to 53.96)	26.67 (4.29 to 49.05)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	1.43 (0.00 to 5.36)	1.47 (0.00 to 5.52)		
Week 4	1.43 (0.00 to 5.36)	1.47 (0.00 to 5.52)		
Week 8	2.94 (0.00 to 8.62)	3.03 (0.00 to 8.88)		
Week 12	1.43 (0.00 to 5.36)	9.09 (0.00 to 18.90)		
Week 16	1.43 (0.00 to 5.36)	1.47 (0.00 to 5.52)		
Week 20	23.53 (9.27 to 37.79)	27.27 (12.08 to 42.47)		
Week 28	23.53 (9.27 to 37.79)	42.42 (25.56 to 59.29)		
Week 36	35.29 (19.23 to 51.36)	39.39 (22.72 to 56.07)		

Week 44	23.53 (9.27 to 37.79)	51.52 (34.46 to 68.57)
Week 52	35.29 (19.23 to 51.36)	42.42 (25.56 to 59.29)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Tender/painful Joint Count at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in Tender/painful Joint Count at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

Tender/painful joint count is to count the tender/painful joint based on 68 joints. The 68 joints to be assessed for tenderness are: Upper Body: 2 temporomandibular, 2 sternoclavicular, 2 acromioclavicular; Upper Extremity: 2 shoulder, 2 elbow, 2 wrist (includes radiocarpal, carpal and carpometacarpal considered as one unit), 10 metacarpophalangeals, 2 thumb interphalangeal (IP), 8 proximal interphalangeals, 8 distal interphalangeals; Lower Extremity: 2 hip, 2 knee, 2 ankle, 2 tarsus (includes subtalar, transverse tarsal and tarsometatarsal considered as one unit), 10 metatarsophalangeals (MTP I, II, III, IV, V), 2 great toe interphalangeal (IP), 8 proximal and distal interphalangeal combined (PIP II, III, IV, V). The baseline is defined as the measurements in Day 1. Response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Done/Not Applicable (to be used for artificial or missing joints).

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-3.3 (± 5.23)	-2.7 (± 4.49)	-4.7 (± 6.37)	0.0 (± 2.70)
Week 4	-6.3 (± 7.96)	-5.1 (± 5.43)	-5.6 (± 8.93)	-2.8 (± 4.49)
Week 8	-9.4 (± 7.69)	-6.8 (± 6.49)	-7.9 (± 7.89)	-4.4 (± 6.42)
Week 12	-9.8 (± 8.19)	-8.7 (± 7.27)	-11.3 (± 7.32)	-6.2 (± 8.43)
Week 16	-11.1 (± 8.01)	-10.1 (± 7.33)	-12.0 (± 8.80)	-10.4 (± 8.69)
Week 20	-12.2 (± 8.20)	-10.2 (± 6.60)	-13.6 (± 9.65)	-11.2 (± 10.95)
Week 28	-12.6 (± 8.38)	-10.4 (± 7.04)	-14.9 (± 9.99)	-13.5 (± 12.21)
Week 36	-12.5 (± 8.66)	-10.7 (± 7.00)	-16.2 (± 9.45)	-13.8 (± 11.89)
Week 44	-13.6 (± 8.54)	-11.6 (± 7.91)	-17.9 (± 10.07)	-12.6 (± 13.23)
Week 52	-13.6 (± 9.11)	-11.9 (± 7.69)	-18.9 (± 10.74)	-13.0 (± 12.25)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-1.9 (± 3.27)	-2.1 (± 5.41)		
Week 4	-3.4 (± 5.47)	-4.3 (± 8.25)		
Week 8	-5.0 (± 6.46)	-4.6 (± 8.41)		
Week 12	-6.5 (± 6.69)	-6.4 (± 9.40)		
Week 16	-6.5 (± 5.78)	-6.5 (± 7.81)		
Week 20	-8.8 (± 5.94)	-10.2 (± 7.41)		
Week 28	-9.6 (± 6.39)	-11.4 (± 8.13)		
Week 36	-10.4 (± 6.12)	-11.4 (± 8.82)		
Week 44	-11.3 (± 6.47)	-12.5 (± 9.15)		
Week 52	-10.8 (± 5.53)	-12.2 (± 9.81)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Swollen Joint Count at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in Swollen Joint Count at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

Swollen joint count is one of the specific components of the ACR Assessments used in this study which count the swollen joint based on 66 joints. The 66 joints to be assessed for swelling are the same as those listed above for tenderness assessment, except that the 2 hip joints are not included in the swollen joint count. The Baseline is defined as the measurements in Day 1. Response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Done/Not Applicable (to be used for artificial or missing joints).

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-2.3 (± 3.48)	-2.7 (± 3.73)	-4.6 (± 5.46)	-2.1 (± 3.31)

Week 4	-4.8 (± 4.42)	-4.3 (± 3.64)	-5.5 (± 5.51)	-5.2 (± 8.14)
Week 8	-6.5 (± 5.42)	-5.9 (± 4.50)	-7.9 (± 4.72)	-7.5 (± 7.54)
Week 12	-7.1 (± 5.89)	-6.7 (± 4.69)	-8.7 (± 6.97)	-8.7 (± 8.04)
Week 16	-8.0 (± 5.53)	-7.6 (± 5.10)	-8.9 (± 7.94)	-9.9 (± 8.98)
Week 20	-8.5 (± 5.31)	-8.3 (± 5.12)	-10.5 (± 8.42)	-10.8 (± 9.10)
Week 28	-8.2 (± 4.34)	-7.7 (± 5.27)	-10.0 (± 7.66)	-10.9 (± 9.00)
Week 36	-8.1 (± 4.35)	-8.1 (± 4.97)	-10.5 (± 7.55)	-11.1 (± 9.30)
Week 44	-8.3 (± 4.87)	-8.2 (± 5.05)	-10.5 (± 6.84)	-10.8 (± 9.93)
Week 52	-8.2 (± 4.84)	-8.1 (± 4.84)	-11.1 (± 7.68)	-10.7 (± 9.55)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-2.0 (± 3.82)	-2.0 (± 3.95)		
Week 4	-2.5 (± 3.11)	-3.6 (± 5.61)		
Week 8	-4.4 (± 5.42)	-4.4 (± 5.95)		
Week 12	-5.4 (± 5.26)	-4.7 (± 6.05)		
Week 16	-6.7 (± 5.80)	-5.5 (± 6.74)		
Week 20	-8.0 (± 6.29)	-7.6 (± 5.15)		
Week 28	-7.2 (± 5.79)	-8.5 (± 5.83)		
Week 36	-8.4 (± 5.60)	-8.9 (± 5.71)		
Week 44	-8.3 (± 5.57)	-9.5 (± 5.51)		
Week 52	-8.5 (± 5.76)	-9.2 (± 6.19)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Patient's Assessment of Arthritis Pain at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in Patient's Assessment of Arthritis Pain at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

Patient's Assessment of Arthritis Pain is one of the specific components of the ACR Assessments used in this study. Subjects will assess the severity of their arthritis pain using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain. Rescaled VAS score is used. Rescaled VAS score (mm) = (100 mm) x (length at mark in mm/overall length of line in mm). The Baseline is defined as the measurements in Day 1. All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Millimeter (mm)				
arithmetic mean (standard deviation)				
Week 2	-7.6 (± 19.13)	-8.0 (± 17.96)	-5.3 (± 12.87)	1.7 (± 21.20)
Week 4	-13.4 (± 23.39)	-18.5 (± 20.32)	-12.4 (± 22.60)	-7.9 (± 22.69)
Week 8	-20.6 (± 23.55)	-21.0 (± 22.46)	-14.3 (± 27.34)	-10.7 (± 25.94)
Week 12	-24.7 (± 25.72)	-22.8 (± 22.19)	-21.8 (± 24.25)	-14.9 (± 24.90)
Week 16	-28.4 (± 24.13)	-25.0 (± 22.58)	-26.5 (± 23.41)	-30.2 (± 20.55)
Week 20	-29.5 (± 24.12)	-30.9 (± 22.91)	-29.3 (± 24.07)	-25.5 (± 29.91)
Week 28	-29.7 (± 22.88)	-32.2 (± 25.21)	-34.6 (± 21.85)	-35.2 (± 24.79)
Week 36	-31.6 (± 25.14)	-31.3 (± 26.58)	-37.0 (± 29.87)	-33.5 (± 36.99)
Week 44	-32.8 (± 26.90)	-36.5 (± 26.87)	-41.6 (± 16.12)	-34.1 (± 39.69)
Week 52	-31.4 (± 26.39)	-35.5 (± 27.76)	-39.6 (± 21.95)	-34.9 (± 31.79)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Millimeter (mm)				
arithmetic mean (standard deviation)				
Week 2	-2.3 (± 11.89)	-9.0 (± 17.52)		
Week 4	-10.1 (± 18.67)	-9.6 (± 18.15)		
Week 8	-16.9 (± 22.67)	-13.1 (± 22.88)		
Week 12	-14.2 (± 24.54)	-12.3 (± 24.44)		
Week 16	-13.7 (± 22.14)	-14.6 (± 20.16)		
Week 20	-32.1 (± 22.84)	-27.7 (± 26.78)		
Week 28	-29.6 (± 27.49)	-37.4 (± 25.54)		
Week 36	-32.4 (± 21.11)	-38.5 (± 26.34)		
Week 44	-35.0 (± 23.36)	-40.0 (± 26.21)		

| | Week 52 | -38.3 (± 22.84) | -38.5 (± 25.29) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Patient's Global Assessment of Arthritis at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in Patient's Global Assessment of Arthritis at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

Patient's Global Assessment of Arthritis is one of the specific components of the ACR Assessments used in this study. Subjects will answer the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response will be recorded using a 100 mm visual analog scale (VAS). Rescaled VAS score is used. Rescaled VAS score (mm) = (100 mm) x (length at mark in mm/overall length of line in mm). The Baseline is defined as the measurements in Day 1. Number of subjects analyzed: All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Millimeter (mm)				
arithmetic mean (standard deviation)				
Week 2	-6.3 (± 21.52)	-10.9 (± 17.85)	-5.4 (± 17.59)	2.6 (± 19.66)
Week 4	-14.4 (± 25.55)	-20.5 (± 20.60)	-12.3 (± 18.09)	-8.9 (± 16.46)
Week 8	-19.4 (± 24.61)	-21.9 (± 24.29)	-14.0 (± 21.37)	-12.7 (± 19.88)
Week 12	-21.8 (± 26.15)	-26.2 (± 21.18)	-20.0 (± 24.36)	-12.4 (± 21.29)
Week 16	-27.8 (± 22.31)	-27.3 (± 21.62)	-26.1 (± 25.26)	-26.7 (± 19.05)
Week 20	-26.8 (± 23.84)	-31.4 (± 21.81)	-27.6 (± 23.49)	-22.8 (± 31.26)
Week 28	-29.4 (± 20.78)	-34.0 (± 23.87)	-33.9 (± 22.09)	-33.7 (± 23.46)
Week 36	-30.1 (± 23.65)	-34.1 (± 26.03)	-37.2 (± 29.10)	-30.7 (± 39.29)
Week 44	-31.5 (± 24.77)	-34.9 (± 24.41)	-38.2 (± 22.88)	-33.0 (± 39.17)
Week 52	-32.0 (± 24.63)	-35.2 (± 28.60)	-36.8 (± 23.09)	-29.6 (± 32.56)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Millimeter (mm)				
arithmetic mean (standard deviation)				
Week 2	-0.1 (± 17.33)	-7.8 (± 17.02)		
Week 4	-2.0 (± 20.76)	-3.3 (± 17.34)		
Week 8	-11.0 (± 26.22)	-7.0 (± 22.38)		
Week 12	-12.2 (± 26.00)	-8.0 (± 25.46)		
Week 16	-9.3 (± 23.48)	-9.4 (± 21.11)		
Week 20	-28.8 (± 25.44)	-25.5 (± 24.96)		
Week 28	-31.7 (± 24.10)	-33.9 (± 23.79)		
Week 36	-28.5 (± 21.25)	-34.9 (± 24.80)		
Week 44	-28.7 (± 23.22)	-35.6 (± 26.55)		
Week 52	-34.9 (± 25.24)	-32.1 (± 28.85)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Physician's Global Assessment of Arthritis at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in Physician's Global Assessment of Arthritis at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

Physician's Global Assessment of Arthritis is one of the specific components of the ACR Assessments used in this study. The blinded assessor will assess how the subject's overall arthritis appears at the time of the visit. This is an evaluation based on the subject's disease signs, functional capacity and physical examination, and should be independent of the Patient's Global Assessment of Arthritis. The investigator's response will be recorded using a 100 mm visual analog scale (VAS). Rescaled VAS score is used. Rescaled VAS score (mm) = (100 mm) x (length at mark in mm/overall length of line in mm). The Baseline is defined as the measurements in Day 1. Number of subjects analyzed: All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Millimeter (mm)				
arithmetic mean (standard deviation)				
Week 2	-9.2 (± 15.59)	-9.0 (± 14.87)	-9.9 (± 14.55)	-1.9 (± 10.79)
Week 4	-19.8 (± 18.98)	-17.6 (± 18.37)	-18.3 (± 22.31)	-11.1 (± 13.99)
Week 8	-30.6 (± 19.43)	-25.0 (± 18.02)	-28.7 (± 15.73)	-16.4 (± 21.08)
Week 12	-35.2 (± 19.92)	-30.1 (± 16.85)	-31.1 (± 20.62)	-21.2 (± 22.01)
Week 16	-37.7 (± 20.59)	-33.7 (± 17.89)	-31.2 (± 20.00)	-32.5 (± 23.98)
Week 20	-41.8 (± 19.91)	-37.8 (± 19.48)	-38.7 (± 24.67)	-34.7 (± 26.16)
Week 28	-42.0 (± 21.42)	-36.7 (± 21.91)	-47.6 (± 21.44)	-42.4 (± 23.28)
Week 36	-42.7 (± 22.92)	-36.8 (± 23.05)	-46.3 (± 22.42)	-43.4 (± 20.30)
Week 44	-44.5 (± 20.15)	-40.6 (± 22.19)	-51.9 (± 15.81)	-43.2 (± 25.55)
Week 52	-46.6 (± 21.73)	-43.4 (± 20.36)	-54.1 (± 15.18)	-42.7 (± 23.34)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Millimeter (mm)				
arithmetic mean (standard deviation)				
Week 2	-3.4 (± 11.92)	-7.2 (± 13.64)		
Week 4	-8.8 (± 17.67)	-9.5 (± 18.08)		
Week 8	-16.3 (± 20.97)	-11.9 (± 17.94)		
Week 12	-16.5 (± 21.57)	-13.7 (± 22.30)		
Week 16	-16.5 (± 23.34)	-14.4 (± 27.76)		
Week 20	-31.0 (± 22.29)	-27.1 (± 25.41)		
Week 28	-32.7 (± 22.03)	-38.8 (± 20.53)		
Week 36	-38.0 (± 19.52)	-42.6 (± 20.41)		
Week 44	-36.4 (± 20.54)	-44.9 (± 20.40)		
Week 52	-36.3 (± 21.01)	-41.9 (± 22.66)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index (DI) at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index (DI) at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The HAQ DI is one of the specific components of the ACR Assessments used in this study. The HAQ DI assesses the degree of difficulty a subject has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 23 items. For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 representing "no difficulty," 1 as "some difficulty," 2 as "much difficulty," and 3 as "unable to do". Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. The Baseline is defined as the measurements in Day 1. Number of subjects analyzed: All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.133 (± 0.4273)	-0.177 (± 0.3489)	-0.195 (± 0.2886)	-0.117 (± 0.4212)
Week 4	-0.248 (± 0.5341)	-0.315 (± 0.3777)	-0.180 (± 0.2090)	-0.217 (± 0.3356)
Week 8	-0.343 (± 0.5690)	-0.421 (± 0.4103)	-0.188 (± 0.4472)	-0.277 (± 0.3609)
Week 12	-0.366 (± 0.5701)	-0.478 (± 0.4167)	-0.214 (± 0.4230)	-0.304 (± 0.2930)
Week 16	-0.474 (± 0.5158)	-0.509 (± 0.3994)	-0.321 (± 0.3914)	-0.375 (± 0.3385)
Week 20	-0.466 (± 0.5546)	-0.576 (± 0.4906)	-0.404 (± 0.4681)	-0.308 (± 0.4610)
Week 28	-0.524 (± 0.5412)	0.583 (± 0.5262)	-0.519 (± 0.4531)	-0.490 (± 0.5064)
Week 36	-0.520 (± 0.6051)	-0.594 (± 0.4990)	-0.577 (± 0.5740)	-0.519 (± 0.5633)
Week 44	-0.521 (± 0.6197)	-0.581 (± 0.5321)	-0.563 (± 0.3830)	-0.510 (± 0.5576)
Week 52	-0.503 (± 0.6023)	-0.567 (± 0.4866)	-0.500 (± 0.5137)	-0.552 (± 0.5041)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.030 (± 0.4572)	-0.170 (± 0.3091)		
Week 4	-0.095 (± 0.4931)	-0.170 (± 0.3305)		
Week 8	-0.184 (± 0.4959)	-0.249 (± 0.4465)		
Week 12	-0.121 (± 0.4910)	-0.239 (± 0.4660)		
Week 16	-0.109 (± 0.5271)	-0.246 (± 0.3729)		
Week 20	-0.363 (± 0.4983)	-0.472 (± 0.4934)		
Week 28	-0.422 (± 0.4811)	-0.517 (± 0.5520)		
Week 36	-0.329 (± 0.3816)	-0.547 (± 0.5867)		
Week 44	-0.370 (± 0.4210)	-0.576 (± 0.5757)		
Week 52	-0.411 (± 0.3695)	-0.514 (± 0.5704)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in High Sensitivity C-reactive Protein (hsCRP) at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change from Baseline in High Sensitivity C-reactive Protein (hsCRP) at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

C-reactive protein (hsCRP) is one of the specific components of the ACR Assessments used in this study. Blood samples for determination of hsCRP were obtained at the times specified above. The Baseline is defined as the measurements in Day 1. All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: milligram per liter (mg/L)				
arithmetic mean (standard deviation)				
Week 2	-4.420 (± 8.9409)	-3.696 (± 11.9628)	-6.023 (± 19.1126)	-0.595 (± 1.4661)
Week 4	-3.645 (± 11.8144)	-5.543 (± 11.9617)	-6.134 (± 19.5633)	-1.324 (± 1.9735)
Week 8	-3.828 (± 10.8093)	-5.102 (± 11.5408)	-6.029 (± 19.9534)	-0.573 (± 2.6595)
Week 12	-3.759 (± 11.0481)	-5.881 (± 12.9484)	-7.335 (± 22.0149)	-1.177 (± 3.4854)
Week 16	-3.695 (± 8.1064)	-5.809 (± 13.6463)	-5.420 (± 21.9622)	1.060 (± 8.7842)
Week 20	-4.581 (± 10.5026)	-6.014 (± 14.7723)	-7.879 (± 24.2763)	-0.989 (± 3.6969)
Week 28	-4.277 (± 12.9069)	-6.362 (± 13.6372)	-8.679 (± 24.9759)	-1.300 (± 3.7971)
Week 36	-4.899 (± 10.3015)	-5.940 (± 14.4219)	-9.461 (± 25.7767)	-1.814 (± 3.0658)
Week 44	-5.543 (± 11.7058)	-6.215 (± 14.2493)	-2.196 (± 2.2859)	-0.987 (± 3.7325)
Week 52	-5.167 (± 13.3963)	-4.880 (± 14.1148)	-1.586 (± 3.0576)	-2.028 (± 3.2177)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: milligram per liter (mg/L)				
arithmetic mean (standard deviation)				
Week 2	-1.641 (± 10.4224)	1.462 (± 7.8966)		
Week 4	0.010 (± 7.0206)	1.206 (± 5.4423)		
Week 8	-2.598 (± 10.7270)	0.927 (± 6.2062)		
Week 12	-1.061 (± 11.1944)	1.021 (± 6.6025)		
Week 16	-2.218 (± 11.6164)	-0.762 (± 6.5779)		
Week 20	-5.982 (± 10.4711)	-4.718 (± 7.1896)		
Week 28	-6.112 (± 10.6756)	-5.484 (± 10.0475)		
Week 36	-6.247 (± 9.8145)	-5.029 (± 9.1947)		
Week 44	-4.690 (± 9.9495)	-0.711 (± 13.7530)		
Week 52	-4.324 (± 7.7335)	-4.722 (± 9.3318)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The PASI quantifies the severity of a subject's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 indicates a 75% or greater reduction in PASI scores from baseline. Number of subjects analyzed: subjects who had baseline BSA>=3% and PASI>0 and had response.

End point type	Secondary

End point timeframe:

Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	39	12	9
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	5.00 (0.00 to 11.75)	2.56 (0.00 to 7.52)	3.85 (0.00 to 14.30)	11.11 (0.00 to 31.64)
Week 4	30.00 (15.80 to 44.20)	12.82 (2.33 to 23.31)	3.85 (0.00 to 14.30)	11.11 (0.00 to 31.64)
Week 8	45.00 (29.58 to 60.42)	41.03 (25.59 to 56.46)	25.00 (0.50 to 49.50)	11.11 (0.00 to 31.64)
Week 12	60.00 (44.82 to 75.18)	48.72 (33.03 to 64.41)	33.33 (6.66 to 60.01)	33.33 (2.54 to 64.13)
Week 16	69.23 (54.75 to 83.72)	58.97 (43.54 to 74.41)	58.33 (30.44 to 86.23)	55.56 (23.09 to 88.02)
Week 20	72.50 (58.66 to 86.34)	61.54 (46.27 to 76.81)	66.67 (39.99 to 93.34)	55.56 (23.09 to 88.02)
Week 28	70.00 (55.80 to 84.20)	51.28 (35.59 to 66.97)	91.67 (76.03 to 100.00)	77.78 (50.62 to 100.00)
Week 36	70.00 (55.80 to 84.20)	64.10 (49.05 to 79.16)	96.15 (85.70 to 100.00)	88.89 (68.36 to 100.00)

Week 44	75.00 (61.58 to 88.42)	66.67 (51.87 to 81.46)	75.00 (50.50 to 99.50)	55.56 (23.09 to 88.02)
Week 52	65.00 (50.22 to 79.78)	66.67 (51.87 to 81.46)	66.67 (39.99 to 93.34)	66.67 (35.87 to 97.46)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	22	19		
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	2.17 (0.00 to 8.13)	5.26 (0.00 to 15.30)		
Week 4	4.55 (0.00 to 13.25)	5.26 (0.00 to 15.30)		
Week 8	9.09 (0.00 to 21.10)	15.79 (0.00 to 32.19)		
Week 12	18.18 (2.06 to 34.30)	21.05 (2.72 to 39.38)		
Week 16	22.73 (5.22 to 40.24)	26.32 (6.52 to 46.12)		
Week 20	54.55 (33.74 to 75.35)	36.84 (15.15 to 58.53)		
Week 28	63.64 (43.54 to 83.74)	63.16 (41.47 to 84.85)		
Week 36	59.09 (38.55 to 79.64)	47.37 (24.92 to 69.82)		
Week 44	63.64 (43.54 to 83.74)	63.16 (41.47 to 84.85)		
Week 52	50.00 (29.11 to 70.89)	57.89 (35.69 to 80.10)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving a PASI 90 Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving a PASI 90 Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The PASI quantifies the severity of a subject's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 indicates a 90% or greater reduction in PASI scores from baseline. Number of subjects analyzed: subjects who had baseline BSA>=3% and PASI>0 and had response.

End point type	Secondary

End point timeframe:

Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	39	12	9
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	1.22 (0.00 to 4.58)	1.25 (0.00 to 4.69)	3.85 (0.00 to 14.30)	11.11 (0.00 to 31.64)
Week 4	17.50 (5.72 to 29.28)	5.13 (0.00 to 12.05)	3.85 (0.00 to 14.30)	11.11 (0.00 to 31.64)
Week 8	35.00 (20.22 to 49.78)	17.95 (5.90 to 29.99)	16.67 (0.00 to 37.75)	11.11 (0.00 to 31.64)
Week 12	47.50 (32.02 to 62.98)	25.64 (11.94 to 39.35)	16.67 (0.00 to 37.75)	22.22 (0.00 to 49.38)
Week 16	53.85 (38.20 to 69.49)	33.33 (18.54 to 48.13)	33.33 (6.66 to 60.01)	33.33 (2.54 to 64.13)
Week 20	50.00 (34.51 to 65.49)	43.59 (28.03 to 59.15)	50.00 (21.71 to 78.29)	44.44 (11.98 to 76.91)
Week 28	52.50 (37.02 to 67.98)	38.46 (23.19 to 53.73)	58.33 (30.44 to 86.23)	44.44 (11.98 to 76.91)
Week 36	62.50 (47.50 to 77.50)	48.72 (33.03 to 64.41)	83.33 (62.25 to 100.00)	66.67 (35.87 to 97.46)
Week 44	52.50 (37.02 to 67.98)	48.72 (33.03 to 64.41)	66.67 (39.99 to 93.34)	44.44 (11.98 to 76.91)
Week 52	40.00 (24.82 to 55.18)	56.41 (40.85 to 71.97)	66.67 (39.99 to 93.34)	55.56 (23.09 to 88.02)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	22	19		
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	2.17 (0.00 to 8.13)	2.50 (0.00 to 9.34)		
Week 4	4.55 (0.00 to 13.25)	2.50 (0.00 to 9.34)		
Week 8	2.17 (0.00 to 8.13)	5.26 (0.00 to 15.30)		
Week 12	2.17 (0.00 to 8.13)	10.53 (0.00 to 24.33)		
Week 16	9.09 (0.00 to 21.10)	15.79 (0.00 to 32.19)		
Week 20	18.18 (2.06 to 34.30)	26.32 (6.52 to 46.12)		
Week 28	50.00 (29.11 to 70.89)	31.58 (10.68 to 52.48)		

Week 36	45.45 (24.65 to 66.26)	36.84 (15.15 to 58.53)		
Week 44	50.00 (29.11 to 70.89)	52.63 (30.18 to 75.08)		
Week 52	45.45 (24.65 to 66.26)	47.37 (24.92 to 69.82)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving a PASI 100 Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving a PASI 100 Response at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The PASI quantifies the severity of a subject's psoriasis based on both lesion severity and the percentage of body surface area (BSA) affected. Assessments of lesion Severity Score and Area Score are performed separately for each of the four body regions: head (including neck), upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). In each body region, the sum of the lesion Severity Scores for erythema, induration and scaling is multiplied by the Area Score which represents the percentage of this area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 100 indicates a 100% or greater reduction in PASI scores from baseline. Number of subjects analyzed: subjects who had baseline BSA>=3% and PASI>0 and had response.

End point type	Secondary

End point timeframe:

Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	39	12	9
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	1.22 (0.00 to 4.58)	1.25 (0.00 to 4.69)	3.85 (0.00 to 14.30)	11.11 (0.00 to 31.64)
Week 4	7.50 (0.00 to 15.66)	1.25 (0.00 to 4.69)	3.85 (0.00 to 14.30)	5.00 (0.00 to 18.51)
Week 8	20.00 (7.60 to 32.40)	5.13 (0.00 to 12.05)	8.33 (0.00 to 23.97)	11.11 (0.00 to 31.64)
Week 12	35.00 (20.22 to 49.78)	7.69 (0.00 to 16.06)	8.33 (0.00 to 23.97)	11.11 (0.00 to 31.64)
Week 16	35.90 (20.84 to 50.95)	15.38 (4.06 to 26.71)	16.67 (0.00 to 37.75)	33.33 (2.54 to 64.13)
Week 20	27.50 (13.66 to 41.34)	35.90 (20.84 to 50.95)	33.33 (6.66 to 60.01)	44.44 (11.98 to 76.91)
Week 28	35.00 (20.22 to 49.78)	30.77 (16.28 to 45.25)	50.00 (21.71 to 78.29)	44.44 (11.98 to 76.91)

Week 36	40.00 (24.82 to 55.18)	35.90 (20.84 to 50.95)	50.00 (21.71 to 78.29)	55.56 (23.09 to 88.02)
Week 44	30.00 (15.80 to 44.20)	41.03 (25.59 to 56.46)	58.33 (30.44 to 86.23)	44.44 (11.98 to 76.91)
Week 52	35.00 (20.22 to 49.78)	38.46 (23.19 to 53.73)	41.67 (13.77 to 69.56)	33.33 (2.54 to 64.13)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	22	19		
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 2	2.17 (0.00 to 8.13)	2.50 (0.00 to 9.34)		
Week 4	4.55 (0.00 to 13.25)	2.50 (0.00 to 9.34)		
Week 8	2.17 (0.00 to 8.13)	2.50 (0.00 to 9.34)		
Week 12	2.17 (0.00 to 8.13)	5.26 (0.00 to 15.30)		
Week 16	9.09 (0.00 to 21.10)	10.53 (0.00 to 24.33)		
Week 20	13.64 (0.00 to 27.98)	10.53 (0.00 to 24.33)		
Week 28	40.91 (20.36 to 61.45)	21.05 (2.72 to 39.38)		
Week 36	36.36 (16.26 to 56.46)	21.05 (2.72 to 39.38)		
Week 44	31.82 (12.36 to 51.28)	42.11 (19.90 to 64.31)		
Week 52	36.36 (16.26 to 56.46)	42.11 (19.90 to 64.31)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Enthesitis Score (Using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index) at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in the Enthesitis Score (Using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index) at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The SPARCC Enthesitis Index examines tenderness at sixteen sites: medial epicondyle humerus, lateral epicondyle humerus, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior border of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle (considered 1 site for scoring purposes), Achilles tendon insertion into calcaneum and plantar fascia insertion into calcaneum. Each site is classified on a dichotomous basis as either tender (score=1) or not tender (score=0). The SPARCC Enthesitis Index scores range from 016, with higher scores indicating higher disease activity. The Baseline is defined as the measurements in Day 1. Number of subjects analyzed: subjects available in the evaluable population (subjects who were

randomized to the study and received at least one dose of the randomized study treatment) at the specified treatment timepoints with baseline SPARCC enthesitis score>0.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	34	11	9
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.6 (± 1.55)	-0.3 (± 2.73)	-1.4 (± 1.86)	0.0 (± 1.12)
Week 4	-1.4 (± 2.41)	-0.9 (± 2.32)	-1.3 (± 2.37)	0.0 (± 1.41)
Week 8	-1.9 (± 2.11)	-1.9 (± 2.23)	-1.4 (± 1.80)	-1.0 (± 1.07)
Week 12	-2.1 (± 2.49)	-1.6 (± 2.22)	-2.7 (± 1.73)	-1.3 (± 1.04)
Week 16	-2.1 (± 2.68)	-1.3 (± 1.89)	-3.1 (± 1.27)	-0.3 (± 2.71)
Week 20	-2.3 (± 2.66)	-1.9 (± 2.29)	-3.2 (± 3.03)	-1.3 (± 0.89)
Week 28	-2.4 (± 2.68)	-2.3 (± 2.60)	-3.8 (± 2.05)	-1.4 (± 1.19)
Week 36	-2.6 (± 2.70)	-2.3 (± 2.28)	-3.8 (± 1.79)	-1.6 (± 1.06)
Week 44	-2.9 (± 2.56)	-2.4 (± 2.53)	-3.3 (± 1.67)	-1.6 (± 1.06)
Week 52	-3.1 (± 2.55)	-2.4 (± 2.34)	-4.8 (± 2.76)	-1.5 (± 0.76)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21	19		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.2 (± 1.79)	-0.3 (± 2.67)		
Week 4	-1.0 (± 2.29)	-1.0 (± 2.81)		
Week 8	-1.1 (± 2.50)	-1.2 (± 2.53)		
Week 12	-1.7 (± 2.52)	-1.1 (± 3.00)		
Week 16	-1.8 (± 2.94)	-1.2 (± 2.79)		
Week 20	-2.1 (± 2.24)	-1.9 (± 2.71)		
Week 28	-2.5 (± 2.97)	-3.1 (± 2.60)		
Week 36	-2.1 (± 2.51)	-2.8 (± 2.60)		
Week 44	-2.1 (± 2.57)	-3.2 (± 2.44)		
Week 52	-2.2 (± 1.74)	-3.6 (± 2.59)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Enthesitis Score (Using the Leeds Enthesitis Index) at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in the Enthesitis Score (Using the Leeds Enthesitis Index) at All Treatment Timepoints: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The Leeds Enthesitis Index (LEI) examines tenderness at six sites: lateral epicondyle humerus, medial femoral condyle and Achilles tendon insertion. Each site is assessed as either tender (score=1) or not tender (score=0). The LEI scores range from 06, with higher scores indicating higher disease activity. The Baseline is defined as the measurements in Day 1. Number of subjects analyzed: subjects available in the evaluable population (subjects who were randomized to the study and received at least one dose of the randomized study treatment) at the specified treatment timepoints with baseline leeds enthesitis score>0.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	28	10	8
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.4 (± 0.95)	-0.4 (± 1.53)	-0.5 (± 1.27)	0.0 (± 0.53)
Week 4	-0.7 (± 1.56)	-0.9 (± 1.48)	-1.0 (± 1.25)	-0.1 (± 0.99)
Week 8	-1.3 (± 1.43)	-1.2 (± 1.47)	-0.5 (± 1.78)	-0.4 (± 0.98)
Week 12	-1.2 (± 1.93)	-1.5 (± 1.42)	-1.0 (± 1.22)	-1.1 (± 0.90)
Week 16	-1.4 (± 1.63)	-1.5 (± 1.45)	-1.2 (± 0.83)	-0.1 (± 2.12)
Week 20	-1.6 (± 1.52)	-1.3 (± 1.80)	-1.7 (± 2.65)	-0.9 (± 0.90)
Week 28	-1.4 (± 1.56)	-1.7 (± 1.57)	-1.9 (± 2.20)	-1.3 (± 0.76)
Week 36	-1.9 (± 1.36)	-1.8 (± 1.59)	-2.3 (± 1.50)	-1.1 (± 0.90)
Week 44	-1.8 (± 1.47)	-1.8 (± 1.65)	-2.3 (± 1.04)	-1.3 (± 0.76)
Week 52	-2.0 (± 1.54)	-1.7 (± 1.40)	-2.5 (± 0.93)	-1.0 (± 0.82)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	15		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.1 (± 1.12)	-0.3 (± 0.82)		
Week 4	-0.4 (± 0.75)	-0.9 (± 1.62)		
Week 8	-0.5 (± 1.31)	-0.7 (± 1.49)		
Week 12	-0.9 (± 0.94)	-0.9 (± 1.79)		

Week 16	-0.9 (± 1.13)	-0.9 (± 1.54)		
Week 20	-1.1 (± 0.90)	-1.4 (± 1.91)		
Week 28	-1.1 (± 1.20)	-1.7 (± 1.54)		
Week 36	-1.1 (± 1.17)	-1.7 (± 1.44)		
Week 44	-1.2 (± 1.19)	-1.9 (± 1.41)		
Week 52	-1.2 (± 0.73)	-1.8 (± 1.70)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Dactylitis Severity Score (DSS) at all treatment time points: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in Dactylitis Severity Score (DSS) at all treatment time points: Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The number of digits in hands and feet with dactylitis was evaluated by a blinded assessor. In addition, dactylitis severity was scored based upon digit tenderness using a scale of 03, where 0 = no tenderness and 3 = extreme tenderness, in each digit of the hands and feet. The range of total dactylitis scores for a subject would be 060. The Baseline is defined as the measurements in Day 1. Number of subjects analyzed: subjects available in the evaluable population (subject who were randomized to the study and received at least one dose of the randomized study treatment) at the specified treatment timepoints with baseline DSS >0.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14	19	3	6
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.2 (± 2.36)	-0.7 (± 2.54)	-2.7 (± 4.62)	-0.5 (± 1.38)
Week 4	-1.6 (± 3.30)	-2.2 (± 3.15)	-3.3 (± 3.21)	-0.8 (± 1.17)
Week 8	-3.5 (± 4.31)	-4.0 (± 3.22)	-4.3 (± 4.16)	-1.7 (± 1.37)
Week 12	-4.4 (± 3.34)	-4.5 (± 3.30)	-4.3 (± 4.93)	-3.2 (± 3.43)
Week 16	-3.7 (± 3.85)	-4.9 (± 4.06)	-4.7 (± 6.35)	-3.7 (± 4.13)
Week 20	-4.4 (± 3.31)	-4.6 (± 4.23)	-5.3 (± 5.86)	-3.7 (± 4.13)
Week 28	-3.8 (± 3.67)	-5.1 (± 4.08)	-5.3 (± 5.86)	-3.7 (± 4.13)
Week 36	-4.2 (± 4.02)	-5.1 (± 4.26)	-5.7 (± 5.69)	-3.7 (± 4.13)
Week 44	-5.0 (± 3.65)	-5.4 (± 4.01)	-5.7 (± 5.69)	-3.7 (± 4.13)
Week 52	-5.0 (± 3.65)	-5.4 (± 4.05)	-5.7 (± 5.69)	-3.7 (± 4.13)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	12	9		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.7 (± 1.61)	0.2 (± 2.28)		
Week 4	-1.2 (± 2.59)	-0.3 (± 3.12)		
Week 8	-2.5 (± 6.14)	-1.8 (± 2.82)		
Week 12	-4.8 (± 7.07)	-2.8 (± 4.49)		
Week 16	-5.4 (± 7.44)	-2.9 (± 6.01)		
Week 20	-7.0 (± 7.44)	-4.4 (± 6.11)		
Week 28	-6.6 (± 7.18)	-4.7 (± 7.05)		
Week 36	-6.8 (± 7.34)	-5.3 (± 7.40)		
Week 44	-6.8 (± 7.34)	-5.3 (± 7.40)		
Week 52	-5.0 (± 5.40)	-5.7 (± 8.62)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score at All Treatment Timepoints: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Score at All Treatment Timepoints: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

A target finger nail was evaluated by the blinded assessor using the NAPSI scale. At the baseline visit, the worst case fingernail should be chosen and the same nail evaluated consistently through the entire study. Each quadrant of the target nail was graded for nail matrix psoriasis (including any of the following parameters: pitting, leukonychia, red spots in lunula, nail plate crumbling) and nail bed psoriasis (including any of the following parameters: onycholysis, splinter hemorrhages, oil drop (salmon patch) discoloration, nail bed hyperkeratosis), giving that 1 target nail a score of 08 directionality. The Baseline is defined as the measurements in Day 1. Number of subjects analyzed: subjects available in the evaluable population (subject who were randomized to the study and received at least one dose of the randomized study treatment) at the specified treatment timepoints with baseline NAPSI >0.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	40	10	8
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.4 (± 1.55)	0.1 (± 0.65)	-0.4 (± 0.52)	0.3 (± 0.71)
Week 4	-1.0 (± 2.09)	-0.5 (± 1.70)	-0.9 (± 1.10)	-0.3 (± 0.46)

Week 8	-2.0 (± 2.40)	-1.0 (± 1.49)	-1.1 (± 1.52)	-1.1 (± 1.57)
Week 12	-2.8 (± 2.54)	-1.8 (± 2.43)	-0.5 (± 2.88)	-1.9 (± 2.97)
Week 16	-3.2 (± 2.71)	-1.7 (± 2.54)	-1.5 (± 2.00)	-2.9 (± 3.08)
Week 20	-3.7 (± 2.82)	-2.3 (± 2.31)	-2.1 (± 2.41)	-3.1 (± 2.97)
Week 28	-3.9 (± 2.90)	-2.4 (± 2.56)	-3.1 (± 2.12)	-3.3 (± 2.93)
Week 36	-3.9 (± 3.06)	-2.5 (± 2.51)	-3.3 (± 1.98)	-3.3 (± 3.15)
Week 44	-4.2 (± 2.77)	-2.8 (± 2.47)	-4.2 (± 2.05)	-3.8 (± 3.19)
Week 52	-4.2 (± 2.62)	-2.6 (± 2.80)	-3.6 (± 2.07)	-3.7 (± 3.27)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	25	16		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	-0.2 (± 1.04)	0.1 (± 0.25)		
Week 4	-1.0 (± 2.16)	-0.3 (± 0.95)		
Week 8	-1.3 (± 2.55)	-0.6 (± 1.55)		
Week 12	-1.2 (± 2.62)	-1.3 (± 1.82)		
Week 16	-1.4 (± 2.61)	-1.6 (± 1.76)		
Week 20	-2.0 (± 2.61)	-1.9 (± 1.81)		
Week 28	-2.2 (± 2.59)	-2.5 (± 1.83)		
Week 36	-2.8 (± 2.71)	-2.9 (± 1.75)		
Week 44	-2.8 (± 2.61)	-2.6 (± 1.71)		
Week 52	-3.1 (± 2.91)	-2.7 (± 1.30)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Patient's Global Joint and Skin AssessmentVisual Analog Scale (PGJSVAS) at All Treatment Timepoints: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in the Patient's Global Joint and Skin AssessmentVisual Analog Scale (PGJSVAS) at All Treatment Timepoints: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

Subject's perception of disease was assessed using a 100 mm visual analog scale (VAS) by placing a mark on the scale between 0 (excellent) and 100 (poor). The rating corresponds to the way in which the subject felt over the past week in terms of how they were affected by their: 1) psoriasis and arthritis (global, PGA); 2) arthritis only (PJA) and 3) psoriasis only (PSA). Rescaled VAS score is used. Rescaled VAS score (mm) = (100 mm) x (length at mark in mm/overall length of line in mm). The Baseline is defined as the measurements in Day 1. All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: millimeter (mm)				
arithmetic mean (standard deviation)				
Week 2	-8.9 (± 26.88)	-11.6 (± 22.31)	-4.9 (± 12.42)	-0.5 (± 12.41)
Week 4	-17.0 (± 24.93)	-18.8 (± 25.42)	-13.2 (± 18.69)	-7.1 (± 21.61)
Week 8	-21.1 (± 26.95)	-19.7 (± 27.56)	-12.0 (± 26.52)	-16.4 (± 25.36)
Week 12	-25.1 (± 28.18)	-25.3 (± 23.75)	-18.0 (± 21.42)	-17.6 (± 23.70)
Week 16	-29.0 (± 24.78)	-24.5 (± 25.43)	-23.9 (± 21.10)	-27.8 (± 21.23)
Week 20	-29.1 (± 24.08)	-30.5 (± 23.29)	-27.3 (± 24.19)	-22.6 (± 27.92)
Week 28	-30.0 (± 24.53)	-29.7 (± 28.36)	-37.2 (± 22.80)	-38.8 (± 25.73)
Week 36	-29.1 (± 27.81)	-29.6 (± 27.90)	-42.0 (± 26.37)	-33.7 (± 27.04)
Week 44	-33.6 (± 28.52)	-32.4 (± 28.81)	-41.9 (± 19.08)	-36.8 (± 30.62)
Week 52	-33.3 (± 28.68)	-32.7 (± 29.77)	-35.6 (± 26.94)	-33.9 (± 33.45)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: millimeter (mm)				
arithmetic mean (standard deviation)				
Week 2	-3.3 (± 14.50)	-7.1 (± 17.44)		
Week 4	-11.6 (± 22.07)	-6.2 (± 24.53)		
Week 8	-16.8 (± 26.21)	-8.1 (± 24.41)		
Week 12	-14.4 (± 28.78)	-9.5 (± 23.74)		
Week 16	-11.7 (± 23.36)	-9.9 (± 23.87)		
Week 20	-36.3 (± 22.12)	-26.3 (± 29.72)		
Week 28	-37.3 (± 25.35)	-37.2 (± 24.64)		
Week 36	-36.0 (± 22.02)	-39.4 (± 26.35)		
Week 44	-38.2 (± 26.65)	-42.1 (± 27.08)		

Week 52	-39.1 (± 23.78)	-38.3 (± 30.58)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Functional Assessment of Chronic Illness TherapyFatigue (FACITF) at All Treatment Timepoints: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in the Functional Assessment of Chronic Illness TherapyFatigue (FACITF) at All Treatment Timepoints: Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items of Q1 I feel fatigued, Q2 I feel weak all over, Q3 I feel listless ("washed out"), Q4 I feel tired and Q7 I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the score. In cases where some answers are missing, a total score is prorated from the score of the answered items, so long as more than 50% of the items (i.e., at least 7 of 13 for FACIT-F total score, at least 3 of 5 for FACIT-F experience domain score, and at least 5 of 8 for FACIT-F impact domain score) are answered. The Baseline is defined as the measurements in Day 1. All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	2.0 (± 5.82)	3.1 (± 5.85)	0.9 (± 2.60)	1.2 (± 6.45)
Week 4	2.4 (± 7.47)	5.7 (± 7.34)	3.7 (± 5.40)	3.7 (± 8.30)
Week 8	4.2 (± 8.03)	5.6 (± 8.44)	3.6 (± 5.78)	3.8 (± 6.24)
Week 12	4.7 (± 10.17)	7.3 (± 7.96)	3.2 (± 4.10)	6.1 (± 7.85)
Week 16	5.6 (± 7.74)	7.1 (± 9.41)	4.4 (± 5.40)	6.0 (± 6.89)
Week 20	6.6 (± 8.69)	9.5 (± 8.20)	7.2 (± 5.86)	7.0 (± 7.94)
Week 28	7.7 (± 9.67)	9.5 (± 8.22)	7.2 (± 7.73)	12.3 (± 11.48)
Week 36	7.4 (± 9.51)	8.4 (± 8.25)	7.3 (± 5.54)	10.6 (± 11.36)
Week 44	7.8 (± 9.00)	10.0 (± 9.52)	7.9 (± 5.07)	13.1 (± 11.10)
Week 52	7.8 (± 8.54)	10.4 (± 9.86)	9.4 (± 9.01)	12.3 (± 12.74)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 2	0.9 (± 6.95)	2.7 (± 6.07)		
Week 4	3.0 (± 10.76)	2.5 (± 6.98)		
Week 8	3.2 (± 10.31)	3.7 (± 9.92)		
Week 12	5.5 (± 9.55)	3.8 (± 9.85)		
Week 16	4.7 (± 8.10)	4.7 (± 8.99)		
Week 20	8.9 (± 8.11)	9.3 (± 9.20)		
Week 28	9.8 (± 10.02)	11.7 (± 10.41)		
Week 36	9.6 (± 6.48)	11.3 (± 11.23)		
Week 44	7.7 (± 7.89)	11.8 (± 11.35)		
Week 52	10.5 (± 8.91)	10.5 (± 10.62)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the ShortForm36 Health Survey (SF36) Version 2, Acute at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in the ShortForm36 Health Survey (SF36) Version 2, Acute at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH). These domains can also be summarized as physical and mental component scores. The summary component scores are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH. All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The Baseline is defined as the measurements in Day 1. All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 4	3.29 (± 7.092)	4.24 (± 7.602)	2.59 (± 5.263)	1.01 (± 3.944)
Week 8	4.21 (± 8.297)	5.97 (± 8.261)	5.53 (± 9.387)	2.47 (± 3.675)

Week 12	4.09 (± 8.403)	4.86 (± 9.010)	7.28 (± 7.232)	2.29 (± 4.283)
Week 16	5.40 (± 8.239)	7.27 (± 8.627)	6.97 (± 7.223)	5.07 (± 4.763)
Week 20	4.75 (± 8.579)	8.84 (± 8.231)	9.53 (± 8.434)	2.03 (± 6.756)
Week 28	6.16 (± 8.691)	9.06 (± 9.597)	9.42 (± 7.751)	7.84 (± 7.127)
Week 36	6.58 (± 9.510)	7.75 (± 9.233)	9.08 (± 9.789)	6.44 (± 7.245)
Week 44	6.67 (± 9.541)	9.23 (± 9.477)	8.44 (± 9.527)	7.13 (± 6.759)
Week 52	6.52 (± 9.818)	9.98 (± 9.150)	9.55 (± 9.536)	6.64 (± 7.925)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 4	1.66 (± 5.845)	2.64 (± 6.299)		
Week 8	2.57 (± 6.457)	3.04 (± 6.529)		
Week 12	2.22 (± 6.205)	3.07 (± 7.330)		
Week 16	2.36 (± 6.842)	1.79 (± 6.101)		
Week 20	6.14 (± 7.513)	6.25 (± 8.447)		
Week 28	5.67 (± 7.933)	9.22 (± 8.890)		
Week 36	5.96 (± 6.738)	9.41 (± 8.940)		
Week 44	6.00 (± 6.937)	9.18 (± 8.199)		
Week 52	7.21 (± 8.130)	9.84 (± 9.347)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Minimal Disease Activity (MDA) at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving Minimal Disease Activity (MDA) at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

A psoriatic arthritis subject was defined as having MDA response when 5 of the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) PASI score ≤1 or BSA ≤3%; 4) subject Arthritis Pain (VAS) ≤15 mm; 5) participant's global arthritis assessment (VAS) ≤20 mm; 6) HAQ-DI score ≤0.5; 7) tender entheseal points (using Leed's enthesitis Index) ≤1. All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 4	8.33 (1.34 to 15.33)	8.33 (1.34 to 15.33)	6.25 (0.00 to 18.11)	3.13 (0.00 to 11.65)
Week 8	26.67 (15.48 to 37.86)	21.67 (11.24 to 32.09)	18.75 (0.00 to 37.87)	6.67 (0.00 to 19.29)
Week 12	31.67 (19.90 to 43.44)	25.00 (14.04 to 35.96)	18.75 (0.00 to 37.87)	20.00 (0.00 to 40.24)
Week 16	35.59 (23.38 to 47.81)	35.00 (22.93 to 47.07)	18.75 (0.00 to 37.87)	20.00 (0.00 to 40.24)
Week 20	45.00 (32.41 to 57.59)	38.33 (26.03 to 50.64)	25.00 (3.78 to 46.22)	26.67 (4.29 to 49.05)
Week 28	43.33 (30.79 to 55.87)	46.67 (34.04 to 59.29)	31.25 (8.54 to 53.96)	33.33 (9.48 to 57.19)
Week 36	43.33 (30.79 to 55.87)	43.33 (30.79 to 55.87)	50.00 (25.50 to 74.50)	60.00 (35.21 to 84.79)
Week 44	53.33 (40.71 to 65.96)	50.00 (37.35 to 62.65)	31.25 (8.54 to 53.96)	46.67 (21.42 to 71.91)
Week 52	46.67 (34.04 to 59.29)	48.33 (35.69 to 60.98)	31.25 (8.54 to 53.96)	40.00 (15.21 to 64.79)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 4	1.43 (0.00 to 5.36)	3.03 (0.00 to 8.88)		
Week 8	5.88 (0.00 to 13.79)	12.12 (0.99 to 23.26)		
Week 12	5.88 (0.00 to 13.79)	12.12 (0.99 to 23.26)		
Week 16	2.94 (0.00 to 8.62)	3.03 (0.00 to 8.88)		
Week 20	29.41 (14.10 to 44.73)	24.24 (9.62 to 38.86)		
Week 28	32.35 (16.63 to 48.08)	45.45 (28.47 to 62.44)		
Week 36	29.41 (14.10 to 44.73)	57.58 (40.71 to 74.44)		
Week 44	32.35 (16.63 to 48.08)	51.52 (34.46 to 68.57)		
Week 52	41.18 (24.63 to 57.72)	45.45 (28.47 to 62.44)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving Very Low Disease Activity (VLDA) Response at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving Very Low Disease Activity (VLDA) Response at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

A subject was in VLDA when all the 7 following criteria were met: 1) tender joint count ≤1; 2) swollen joint count ≤1; 3) PASI score ≤1 or BSA ≤3%; 4) subject Arthritis Pain (VAS) ≤15 mm; 5) subject's global arthritis assessment (VAS) ≤20 mm; 6) HAQ-DI score ≤0.5; 7) tender entheseal points (using Leed's enthesitis Index) ≤1. All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 4	0.82 (0.00 to 3.08)	0.82 (0.00 to 3.08)	2.94 (0.00 to 10.97)	3.13 (0.00 to 11.65)
Week 8	1.67 (0.00 to 4.91)	1.67 (0.00 to 4.91)	2.94 (0.00 to 10.97)	3.13 (0.00 to 11.65)
Week 12	0.82 (0.00 to 3.08)	3.33 (0.00 to 7.88)	2.94 (0.00 to 10.97)	3.13 (0.00 to 11.65)
Week 16	3.39 (0.00 to 8.01)	5.00 (0.00 to 10.51)	6.25 (0.00 to 18.11)	3.13 (0.00 to 11.65)
Week 20	6.67 (0.35 to 12.98)	11.67 (3.54 to 19.79)	12.50 (0.00 to 28.70)	13.33 (0.00 to 30.54)
Week 28	10.00 (2.41 to 17.59)	10.00 (2.41 to 17.59)	12.50 (0.00 to 28.70)	6.67 (0.00 to 19.29)
Week 36	15.00 (5.97 to 24.03)	15.00 (5.97 to 24.03)	12.50 (0.00 to 28.70)	6.67 (0.00 to 19.29)
Week 44	15.00 (5.97 to 24.03)	16.67 (7.24 to 26.10)	18.75 (0.00 to 37.87)	20.00 (0.00 to 40.24)
Week 52	20.00 (9.88 to 30.12)	16.67 (7.24 to 26.10)	25.00 (3.78 to 46.22)	20.00 (0.00 to 40.24)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Percentage of subjects				

number (confidence interval 95%)				
Week 4	1.43 (0.00 to 5.36)	1.47 (0.00 to 5.52)		
Week 8	1.43 (0.00 to 5.36)	1.47 (0.00 to 5.52)		
Week 12	1.43 (0.00 to 5.36)	1.47 (0.00 to 5.52)		
Week 16	1.43 (0.00 to 5.36)	1.47 (0.00 to 5.52)		
Week 20	2.94 (0.00 to 8.62)	1.47 (0.00 to 5.52)		
Week 28	8.82 (0.00 to 18.36)	6.06 (0.00 to 14.20)		
Week 36	5.88 (0.00 to 13.79)	12.12 (0.99 to 23.26)		
Week 44	14.71 (2.80 to 26.61)	15.15 (2.92 to 27.38)		
Week 52	11.76 (0.93 to 22.59)	18.18 (5.02 to 31.34)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA) at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

DAREA/DAPSA is a composite instrument to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count + swollen joint count (using SJC66/ TJC68 assessments), patient's global assessment of Arthritis (PtGA in cm), patient's assessment of Arthritis Pain (PAIN in cm) and CRP (in mg/dL). Since DAREA reflects domains found important in PsA, it has been proposed to serve as a Disease Activity Index for Psoriatic Arthritis (DAPSA). DAREA/DAPSA is calculated at every study visit during the treatment period except Week 2 visit as follows: DAREA/DAPSA= SJC66 + TJC68 + PtGA + PAIN + CRP. The Baseline is defined as the measurements in Day 1. All subjects who received at least 1 dose of the randomized study treatment with baseline DAREA/DAPSA.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Unit on a scale				
arithmetic mean (standard deviation)				

Week 4	-14.05 (± 11.826)	-13.99 (± 10.166)	-14.15 (± 14.294)	-9.81 (± 13.841)
Week 8	-20.36 (± 11.211)	-17.55 (± 11.664)	-19.19 (± 11.720)	-14.33 (± 15.143)
Week 12	-21.93 (± 12.582)	-20.91 (± 11.985)	-24.91 (± 15.556)	-17.77 (± 18.471)
Week 16	-25.15 (± 12.582)	-23.55 (± 12.040)	-26.65 (± 16.982)	-25.89 (± 18.513)
Week 20	-26.75 (± 13.625)	-25.24 (± 12.152)	-30.63 (± 17.150)	-27.01 (± 22.334)
Week 28	-27.13 (± 12.807)	-25.38 (± 13.129)	-32.63 (± 18.437)	-31.41 (± 22.145)
Week 36	-27.21 (± 14.456)	-25.84 (± 13.170)	-34.98 (± 19.857)	-31.53 (± 24.046)
Week 44	-28.39 (± 14.445)	-27.54 (± 12.744)	-36.61 (± 14.597)	-30.22 (± 27.532)
Week 52	-28.56 (± 15.578)	-27.40 (± 13.429)	-37.81 (± 14.251)	-30.32 (± 22.795)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 4	-7.11 (± 8.738)	-9.08 (± 12.074)		
Week 8	-12.46 (± 12.905)	-10.98 (± 15.222)		
Week 12	-14.68 (± 12.943)	-13.04 (± 15.072)		
Week 16	-15.83 (± 12.918)	-14.45 (± 15.150)		
Week 20	-23.53 (± 13.606)	-23.63 (± 13.640)		
Week 28	-23.54 (± 12.375)	-27.55 (± 14.831)		
Week 36	-25.57 (± 11.445)	-28.22 (± 15.793)		
Week 44	-26.43 (± 10.880)	-29.59 (± 15.962)		
Week 52	-26.45 (± 11.114)	-28.95 (± 17.706)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving the Psoriatic Arthritis Response Criteria (PsARC) at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Percentage of Subjects Achieving the Psoriatic Arthritis Response Criteria (PsARC) at All Treatment Timepoints Except

	Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

The PsARC consists of 4 measurements: Tender joint count (68) - TJC; Swollen joint count (66) - SJC; Physician's Global Assessment of Arthritis (visual analog scale, VAS); Patient's Global Assessment of Arthritis (VAS). Specifically, the PsARC response was defined as improvement in 2 of the following 4 criteria, one of which must be joint pain or swelling, without worsening in any measure: (1) ≥20% improvement in Physician's Global Assessment of Arthritis (VAS); (2) ≥20% improvement in Patient's Global Assessment of Arthritis (VAS); (3) ≥30% improvement in tender joint count (68); and (4) ≥30% improvement in swollen joint count (66). All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 4	50.00 (37.35 to 62.65)	55.00 (42.41 to 67.59)	50.00 (25.50 to 74.50)	40.00 (15.21 to 64.79)
Week 8	66.67 (54.74 to 78.59)	60.00 (47.60 to 72.40)	56.25 (31.94 to 80.56)	40.00 (15.21 to 64.79)
Week 12	66.67 (54.74 to 78.59)	75.00 (64.04 to 85.96)	62.50 (38.78 to 86.22)	60.00 (35.21 to 84.79)
Week 16	83.05 (73.48 to 92.62)	75.00 (64.04 to 85.96)	62.50 (38.78 to 86.22)	66.67 (42.81 to 90.52)
Week 20	78.33 (67.91 to 88.76)	81.67 (71.88 to 91.46)	56.25 (31.94 to 80.56)	60.00 (35.21 to 84.79)
Week 28	81.67 (71.88 to 91.46)	80.00 (69.88 to 90.12)	68.75 (46.04 to 91.46)	73.33 (50.95 to 95.71)
Week 36	66.67 (54.74 to 78.59)	75.00 (64.04 to 85.96)	68.75 (46.04 to 91.46)	80.00 (59.76 to 100.00)
Week 44	66.67 (54.74 to 78.59)	78.33 (67.91 to 88.76)	56.25 (31.94 to 80.56)	73.33 (50.95 to 95.71)
Week 52	58.33 (45.86 to 70.81)	70.00 (58.40 to 81.60)	56.25 (31.94 to 80.56)	66.67 (42.81 to 90.52)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Percentage of subjects				
number (confidence interval 95%)				
Week 4	26.47 (11.64 to 41.30)	21.21 (7.26 to 35.16)		
Week 8	38.24 (21.90 to 54.57)	45.45 (28.47 to 62.44)		
Week 12	52.94 (36.16 to 69.72)	45.45 (28.47 to 62.44)		

Week 16	50.00 (33.19 to 66.81)	48.48 (31.43 to 65.54)		
Week 20	70.59 (55.27 to 85.90)	72.73 (57.53 to 87.92)		
Week 28	73.53 (58.70 to 88.36)	75.76 (61.14 to 90.38)		
Week 36	67.65 (51.92 to 83.37)	84.85 (72.62 to 97.08)		
Week 44	58.82 (42.28 to 75.37)	75.76 (61.14 to 90.38)		
Week 52	64.71 (48.64 to 80.77)	66.67 (50.58 to 82.75)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point title	Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at All Treatment Timepoints Except Week 2: Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point description:

PASDAS is a composite psoriatic arthritis disease activity score that includes the following components: patient's global joint and skin assessment (visual analog scale in mm), physician's global psoriatic arthritis assessment (visual analog scale in mm), swollen (66 joints) and tender joint counts (68 joints), Leeds Enthesitis Index score, tender dactylitic digit score, physical component summary score (PCS) of Short Form 36 Health Survey and C-reactive protein (mg/L). Any missing component would result in PASDAS as missing. A higher PASDAS score indicates a higher disease activity. The baseline was defined as the measurements in Day 1. All subjects who received at least 1 dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 28, 36, 44, and 52

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 4	-1.22 (± 1.119)	-1.31 (± 1.090)	-0.94 (± 0.957)	-0.65 (± 0.653)
Week 8	-1.79 (± 1.295)	-1.65 (± 1.262)	-1.37 (± 1.127)	-1.14 (± 1.122)
Week 12	-2.10 (± 1.380)	-1.93 (± 1.278)	-1.67 (± 0.996)	-1.61 (± 1.106)
Week 16	-2.31 (± 1.302)	-2.20 (± 1.354)	-1.87 (± 1.024)	-2.18 (± 1.286)
Week 20	-2.48 (± 1.338)	-2.48 (± 1.474)	-2.49 (± 1.199)	-2.18 (± 1.441)

Week 28	-2.62 (± 1.354)	-2.60 (± 1.642)	-2.90 (± 1.279)	-3.18 (± 1.484)
Week 36	-2.73 (± 1.509)	-2.59 (± 1.644)	-3.08 (± 1.539)	-2.97 (± 1.550)
Week 44	-2.95 (± 1.421)	-2.85 (± 1.637)	-3.25 (± 0.819)	-3.23 (± 1.833)
Week 52	-3.03 (± 1.487)	-2.98 (± 1.568)	-3.36 (± 0.826)	-3.14 (± 1.461)

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Unit on a scale				
arithmetic mean (standard deviation)				
Week 4	-0.56 (± 0.655)	-0.54 (± 0.897)		
Week 8	-1.02 (± 0.988)	-0.67 (± 1.045)		
Week 12	-1.04 (± 1.101)	-0.80 (± 1.158)		
Week 16	-1.08 (± 1.127)	-0.90 (± 1.193)		
Week 20	-2.37 (± 1.202)	-2.10 (± 1.367)		
Week 28	-2.48 (± 1.181)	-2.81 (± 1.302)		
Week 36	-2.69 (± 1.043)	-2.96 (± 1.425)		
Week 44	-2.73 (± 1.157)	-3.23 (± 1.508)		
Week 52	-2.84 (± 1.399)	-3.07 (± 1.775)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (All Causalities)

End point title	Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) From Baseline (Day 1) Through Week 56 (All Causalities)

End point description:

An AE is any untoward medical occurrence in a study subjects administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the subject or may require intervention to prevent one of the other AE outcomes. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of the study medication. All AEs in the table below were treatment-emergent AEs. All participants who

received at least one dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

From baseline (Day 1) through Week 56

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Subjects				
Subjects with AEs	46	45	10	10
Subjects with SAEs	1	8	0	0
Subjects with severe AEs	1	6	0	0
Subjects discontinued from study due to AEs	0	1	0	0

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Subjects				
Subjects with AEs	24	25		
Subjects with SAEs	1	2		
Subjects with severe AEs	1	2		
Subjects discontinued from study due to AEs	0	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) from Baseline (Day 1) Through Week 56 (Treatment-Related)

End point title	Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) from Baseline (Day 1) Through Week 56 (Treatment-Related)

End point description:

An AE is any untoward medical occurrence in a study subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An SAE is any untoward medical occurrence at any dose that: results in death; is life threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect; or that is considered to be an important medical event that may jeopardize the subject or may require intervention to prevent one of the other AE outcomes. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of

study medication. Treatment-related AEs were determined by the investigators. All participants who received at least one dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

From baseline (Day 1) through Week 56

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Subjects				
Subjects with AEs	17	15	6	2
Subjects with SAEs	0	1	0	0
Subjects with severe AEs	0	1	0	0
Subjects discontinued from study due to AEs	0	1	0	0

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Subjects				
Subjects with AEs	11	10		
Subjects with SAEs	1	1		
Subjects with severe AEs	1	1		
Subjects discontinued from study due to AEs	0	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects who Discontinued From the Study Due to Treatment-Emergent AEs From Baseline (Day 1) Through Week 56

End point title	Number of Subjects who Discontinued From the Study Due to Treatment-Emergent AEs From Baseline (Day 1) Through Week 56

End point description:

An AE is any untoward medical occurrence in a study subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of the study medication. Analysis population is all participants who received at least one dose of the randomized study treatment.

End point type	Secondary

End point timeframe:

From baseline (Day 1) through Week 56

End point values	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	60	16	15
Units: Subjects				
Otitis media acute	0	1	0	0
Upper respiratory tract infection	0	0	0	0
Psoriasis	0	0	0	0

End point values	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	34	33		
Units: Subjects				
Otitis media acute	0	0		
Upper respiratory tract infection	0	1		
Psoriasis	0	1		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the time the subject took at least 1 dose of study treatment up to 28 days after the last treatment administration. (approximately 56 Weeks)

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.1

Reporting groups

Reporting group title	PF-06700841 60 mg QD -> PF-06700841 60 mg QD
Reporting group description:	
Treatment Group Description TBD	
Reporting group title	PF-06700841 30 mg QD -> PF-06700841 30 mg QD
Reporting group description:	
Treatment Group Description TBD	
Reporting group title	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Reporting group description:	
Treatment Group Description TBD	
Reporting group title	PF-06700841 10 mg QD -> PF-06700841 30 mg QD
Reporting group description:	
Treatment Group Description TBD	
Reporting group title	Placebo -> PF-06700841 60 mg QD
Reporting group description:	
Treatment Group Description TBD	
Reporting group title	Placebo -> PF-06700841 30 mg QD
Reporting group description:	
Treatment Group Description TBD	

Serious adverse events	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 60 (1.67%)	8 / 60 (13.33%)	0 / 16 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Radius fracture			
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Lumbar radiculopathy			
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuralgia			
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular encephalopathy			
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Duodenal ulcer			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis chronic			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc disorder			
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovitis			

	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations

Appendicitis

subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

COVID-19 pneumonia

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Otitis media acute

subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia

subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia viral

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Varicella

subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	PF-06700841 10 mg QD -> PF-06700841 30 mg QD	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 15 (0.00%)	1 / 34 (2.94%)	2 / 33 (6.06%)
number of deaths (all causes)	0	0	0
number of deaths resulting from			

adverse events			
Injury, poisoning and procedural complications			
Radius fracture			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Lumbar radiculopathy			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuralgia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular encephalopathy			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Duodenal ulcer			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis chronic			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	1 / 33 (3.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			

Intervertebral disc disorder			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 15 (0.00%)	1 / 34 (2.94%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis media acute			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia viral			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	1 / 33 (3.03%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	PF-06700841 60 mg QD -> PF-06700841 60 mg QD	PF-06700841 30 mg QD -> PF-06700841 30 mg QD	PF-06700841 10 mg QD -> PF-06700841 60 mg QD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 60 (61.67%)	34 / 60 (56.67%)	10 / 16 (62.50%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	5 / 60 (8.33%)	7 / 60 (11.67%)	1 / 16 (6.25%)
occurrences (all)	7	10	3
Blood creatine phosphokinase increased			
subjects affected / exposed	4 / 60 (6.67%)	4 / 60 (6.67%)	1 / 16 (6.25%)
occurrences (all)	4	5	1
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Transaminases increased			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 60 (5.00%)	3 / 60 (5.00%)	0 / 16 (0.00%)
occurrences (all)	5	4	0
Hepatic enzyme increased			
subjects affected / exposed	2 / 60 (3.33%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1
Weight increased			
subjects affected / exposed	1 / 60 (1.67%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Vascular disorders			
Hypertension			
subjects affected / exposed	5 / 60 (8.33%)	2 / 60 (3.33%)	1 / 16 (6.25%)
occurrences (all)	6	2	1
Nervous system disorders			
Headache			
subjects affected / exposed	5 / 60 (8.33%)	4 / 60 (6.67%)	2 / 16 (12.50%)
occurrences (all)	6	6	3

Vertebrobasilar insufficiency			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 60 (3.33%)	2 / 60 (3.33%)	0 / 16 (0.00%)
occurrences (all)	2	2	0
Leukopenia			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	3 / 60 (5.00%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences (all)	3	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 60 (5.00%)	1 / 60 (1.67%)	1 / 16 (6.25%)
occurrences (all)	3	1	1
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	4 / 60 (6.67%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences (all)	6	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1
Dyspepsia			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1
Nausea			
subjects affected / exposed	4 / 60 (6.67%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences (all)	4	1	0
Hepatobiliary disorders			
Liver disorder			

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1

Respiratory, thoracic and mediastinal disorders

Respiratory disorder

subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences (all)	0	1	0

Upper respiratory tract inflammation

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1

Skin and subcutaneous tissue disorders

Skin mass

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1

Acne

subjects affected / exposed	1 / 60 (1.67%)	2 / 60 (3.33%)	1 / 16 (6.25%)
occurrences (all)	1	2	1

Psoriasis

subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	1	0	1

Rash

subjects affected / exposed	2 / 60 (3.33%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	2	0	1

Urticaria

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Psychiatric disorders

Depression

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1

Musculoskeletal and connective tissue disorders

Back pain

subjects affected / exposed	0 / 60 (0.00%)	1 / 60 (1.67%)	1 / 16 (6.25%)
occurrences (all)	0	1	1

Psoriatic arthropathy

subjects affected / exposed	1 / 60 (1.67%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences (all)	1	1	0

Spinal pain			
subjects affected / exposed	1 / 60 (1.67%)	1 / 60 (1.67%)	1 / 16 (6.25%)
occurrences (all)	1	1	1

Infections and infestations

Herpes zoster			
subjects affected / exposed	1 / 60 (1.67%)	1 / 60 (1.67%)	1 / 16 (6.25%)
occurrences (all)	1	1	1
Oral herpes			
subjects affected / exposed	2 / 60 (3.33%)	2 / 60 (3.33%)	1 / 16 (6.25%)
occurrences (all)	2	4	1
Urinary tract infection			
subjects affected / exposed	4 / 60 (6.67%)	4 / 60 (6.67%)	1 / 16 (6.25%)
occurrences (all)	7	5	1
Bronchitis			
subjects affected / exposed	4 / 60 (6.67%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	4	0	1
COVID-19			
subjects affected / exposed	1 / 60 (1.67%)	2 / 60 (3.33%)	0 / 16 (0.00%)
occurrences (all)	1	2	0
Cystitis			
subjects affected / exposed	1 / 60 (1.67%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	2 / 60 (3.33%)	1 / 60 (1.67%)	0 / 16 (0.00%)
occurrences (all)	2	1	0
Nasopharyngitis			
subjects affected / exposed	8 / 60 (13.33%)	5 / 60 (8.33%)	0 / 16 (0.00%)
occurrences (all)	10	5	0
Pharyngitis			
subjects affected / exposed	2 / 60 (3.33%)	2 / 60 (3.33%)	0 / 16 (0.00%)
occurrences (all)	4	2	0
Pneumonia			
subjects affected / exposed	2 / 60 (3.33%)	1 / 60 (1.67%)	1 / 16 (6.25%)
occurrences (all)	2	1	1
Respiratory tract infection			

subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	7 / 60 (11.67%)	5 / 60 (8.33%)	0 / 16 (0.00%)
occurrences (all)	8	6	0
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 60 (0.00%)	0 / 60 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1

Non-serious adverse events	PF-06700841 10 mg QD -> PF-06700841 30 mg QD	Placebo -> PF-06700841 60 mg QD	Placebo -> PF-06700841 30 mg QD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 15 (66.67%)	18 / 34 (52.94%)	20 / 33 (60.61%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 15 (6.67%)	2 / 34 (5.88%)	0 / 33 (0.00%)
occurrences (all)	1	3	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 15 (0.00%)	1 / 34 (2.94%)	2 / 33 (6.06%)
occurrences (all)	0	2	2
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 15 (0.00%)	2 / 34 (5.88%)	0 / 33 (0.00%)
occurrences (all)	0	2	0
Transaminases increased			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 15 (6.67%)	2 / 34 (5.88%)	1 / 33 (3.03%)
occurrences (all)	1	3	1
Hepatic enzyme increased			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 15 (0.00%)	2 / 34 (5.88%)	0 / 33 (0.00%)
occurrences (all)	0	2	0
Vascular disorders			

Hypertension			
subjects affected / exposed	0 / 15 (0.00%)	1 / 34 (2.94%)	1 / 33 (3.03%)
occurrences (all)	0	1	1
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 15 (6.67%)	1 / 34 (2.94%)	3 / 33 (9.09%)
occurrences (all)	1	1	3
Vertebrobasilar insufficiency			
subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 15 (0.00%)	3 / 34 (8.82%)	1 / 33 (3.03%)
occurrences (all)	0	3	1
Leukopenia			
subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	1 / 15 (6.67%)	1 / 34 (2.94%)	0 / 33 (0.00%)
occurrences (all)	1	1	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 15 (0.00%)	1 / 34 (2.94%)	0 / 33 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	1	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			

subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	1 / 33 (3.03%)
occurrences (all)	1	0	1
Nausea			
subjects affected / exposed	0 / 15 (0.00%)	3 / 34 (8.82%)	1 / 33 (3.03%)
occurrences (all)	0	3	1
Hepatobiliary disorders			
Liver disorder			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Respiratory disorder			
subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Skin mass			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 15 (0.00%)	1 / 34 (2.94%)	0 / 33 (0.00%)
occurrences (all)	0	1	0
Psoriasis			
subjects affected / exposed	0 / 15 (0.00%)	1 / 34 (2.94%)	2 / 33 (6.06%)
occurrences (all)	0	1	2
Rash			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	2 / 33 (6.06%)
occurrences (all)	0	0	2
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0

Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	2 / 33 (6.06%)
occurrences (all)	0	0	2
Psoriatic arthropathy			
subjects affected / exposed	0 / 15 (0.00%)	1 / 34 (2.94%)	2 / 33 (6.06%)
occurrences (all)	0	2	2
Spinal pain			
subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	1 / 33 (3.03%)
occurrences (all)	1	0	1
Infections and infestations			
Herpes zoster			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	1 / 15 (6.67%)	1 / 34 (2.94%)	0 / 33 (0.00%)
occurrences (all)	1	1	0
Bronchitis			
subjects affected / exposed	2 / 15 (13.33%)	1 / 34 (2.94%)	1 / 33 (3.03%)
occurrences (all)	2	1	1
COVID-19			
subjects affected / exposed	1 / 15 (6.67%)	1 / 34 (2.94%)	2 / 33 (6.06%)
occurrences (all)	1	1	2
Cystitis			
subjects affected / exposed	0 / 15 (0.00%)	2 / 34 (5.88%)	0 / 33 (0.00%)
occurrences (all)	0	2	0
Gastroenteritis			
subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	2 / 15 (13.33%)	1 / 34 (2.94%)	4 / 33 (12.12%)
occurrences (all)	2	1	4
Pharyngitis			

subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	2 / 33 (6.06%)
occurrences (all)	0	0	2
Pneumonia			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	1 / 33 (3.03%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	1 / 15 (6.67%)	0 / 34 (0.00%)	1 / 33 (3.03%)
occurrences (all)	1	0	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 15 (0.00%)	2 / 34 (5.88%)	3 / 33 (9.09%)
occurrences (all)	0	4	4
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 15 (0.00%)	0 / 34 (0.00%)	0 / 33 (0.00%)
occurrences (all)	0	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 April 2019	Section 4.4.1 Contraception was updated to include an instruction that male subjects should refrain from sperm donation during the study and for a period of at least 90 days after completion of active treatment.
22 October 2019	Section 1.2.6 Summary of Benefit Risk Assessment was amended to reflect some of the updates made in Section 7 of the current Investigator's Brochure (IB), particularly the addition of QT prolongation as a potential risk and the addition of the pulmonary embolism and the adjudication committee for suspected thrombotic and embolic events. Section 4.4.1. Contraception. Sexually active male subjects with female partners of child bearing potential are no longer required to use a condom to prevent potential transfer to and exposure of partner(s) to drug through ejaculate. Appendix 6. Discontinuation Criteria. Additional discontinuation criterion added to clarify that study drug will be discontinued and the subject withdrawn from the study treatment in the event of any of the following: serious thromboembolic events, including venous thrombosis (including but not limited to deep vein thrombosis [DVT], pulmonary embolism [PE]), arterial thrombosis, and cerebrovascular events (thromboembolic stroke, transient ischemic attack [TIA], etc.) requiring hospitalization for treatment, or meeting other criteria that require the thromboembolic event to be classified as a serious adverse event (SAE). Appendix 6. Discontinuation Criteria. Additional discontinuation criteria added to clarify that study drug will be discontinued and the subject withdrawn from the study treatment in the event of any of the following: Two sequential AST or ALT elevation >=3 times the upper limit of normal with at least one total bilirubin value >=2 times the upper limit of normal; Two sequential AST or ALT elevation >=3 times the upper limit of normal accompanied by signs or symptoms consistent with hepatic injury; Two sequential AST or ALT elevation >=5 times the upper limit of normal, regardless of total bilirubin or accompanying signs or symptoms.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

 None reported